

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 263/32, A61K 31/42, C07D 413/12, 413/04		A1	(11) International Publication Number: WO 94/27980
			(43) International Publication Date: 8 December 1994 (08.12.94)
(21) International Application Number: PCT/US94/05395		(74) Agents: BULOCK, Joseph, W. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680- 5110 (US).	
(22) International Filing Date: 19 May 1994 (19.05.94)			
(30) Priority Data: 08/065,730 21 May 1993 (21.05.93) US		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US 08/065,730 (CIP) Filed on 21 May 1994 (21.05.94)		Published With international search report.	
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): NORMAN, Bryan, H. [US/US]; 8648 Admiral Bay Drive, Indianapolis, IN 46236 (US). LEE, Len, F. [US/US]; 2496 Annapolis Way, St. Charles, MO 63303 (US). MASFERRER, Jaime, L. [CL/US]; 1213 Blairshire, Ballwin, MO 63011 (US). TALLEY, John, J. [US/US]; 1079 Darwick Court, St. Louis, MO 63132 (US).			

(54) Title: SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION

(57) Abstract

A class of substituted oxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by formula (I) wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R¹ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R² is alkyl; or a pharmaceutically-acceptable salt thereof; provided R¹ is not phenyl when R² is methyl and R is isopropyl or tert-butyl.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION

FIELD OF THE INVENTION

5

This invention is in the field of anti-inflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating inflammation and inflammation-associated disorders, such as arthritis.

10

BACKGROUND OF THE INVENTION

Prostaglandins play a major role in the inflammation process and the inhibition of prostaglandin production, especially production of PGG₂, PGH₂ and PGE₂, has been a common target of antiinflammatory drug discovery. However, common non-steroidal antiinflammatory drugs (NSAIDs) that are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process are also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAIDs can produce severe side effects, including life threatening ulcers, that limit their therapeutic potential. An alternative to NSAIDs is the use of corticosteroids, which have even more drastic side effects, especially when long term therapy is involved.

25

Previous NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX). Recently, the sequence of another heretofore unknown enzyme in the human arachidonic acid/prostaglandin pathway has been reported by T. Hla and K. Nielson, *Proc. Natl. Acad. Sci, USA*, **89**, 7384 (1992) and named "cyclooxygenase II (COX II)" or "prostaglandin G/H synthase II". The discovery of an inducible enzyme

35

associated with inflammation provides a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects.

5 Cyclooxygenase II is inducible by cytokines or endotoxins and such induction is inhibited by glucocorticoids (J. Masferrer, et al, *Proc. Natl. Acad. Sci, USA*, **89**, 3917 (1992)). The 6-methoxy-2-naphthylacetic acid metabolite of nabumetone has been found by E. Meade et al to selectively inhibit the COX II enzyme (*J. Biol. Chem.*, **268**, 6610
10 (1993)). In addition, Futaki et al (*Prostaglandins*, **47**, 1 (1994)) have reported that N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the COX II enzyme.

The references below that disclose antiinflammatory
15 activity, show continuing efforts to find a safe and effective antiinflammatory agent. The novel oxazoles disclosed herein are such safe and also effective antiinflammatory agents furthering such efforts. The invention compounds are found to show usefulness in vivo as
20 antiinflammatory agents with minimal side effects. The substituted oxazolyl compounds disclosed herein preferably selectively inhibit cyclooxygenase II over cyclooxygenase I.

2,3-Diaryl-5-halo thiophenes are described
25 in U.S. Patent No. 4,590,205 as analgesic or antiinflammatory agents. More particularly, 2,3-diaryl-5-bromo thiophenes are described in U.S. Patent No. 4,820,827 as having antiinflammatory and prostaglandin synthetase inhibitory activity for use
30 in the treatment of inflammation and dysmenorrhea. Copending application Serial No. PCT/US94/466 describes 4,5-substitutedphenylthiophenes as having antiinflammatory activity.

35 Pyrazole derivatives having antiinflammatory activity are described in U.S. Patent No. 5, 134,142, to Matsuo et al.

U.S. Patent No. 3,578,671, to K. Brown, describes antiinflammatory 4,5-diphenyloxazoles substituted in the 2-position by a saturated or unsaturated aliphatic acid. U.S. Patent No. 4,051,250, to J. Dahm et al, describes oxazole, imidazole and thiazole compounds, including 2-mercapto-4-(4-methylmercaptophenyl)-5-(4-chlorophenyl)oxazole, as having antiphlogistic, analgesic and antipyretic activity. Other related diphenyloxazole disclosures include U.S. Patent No. 4,001,228, to G. Mattalia, for antiaggregating activity and U.S. Patent No. 3,895,024, to R. Hafeli, for intermediates in the production of antiinflammatory agents. U. S. Patent No. 4,489,084, to F. Haviv and F.Kerdesky, describes diphenyloxazolyl hydrazinoalkyl nitrile compounds for use as antiinflammatory agents. U.S. Patent No. 4,143,047, to R. Harrison, describes oxazole compounds as reactants to make 2-acylamino oxazole derivatives having anti-allergy activity.

U.S. Patent No. 4,791,124, to Lutomski et al, describes the pesticide activity of substituted bis(4-halophenyl)oxazoles. U.S. Patent No. 4,775,687, to Meguro et al describes the possible use of 4,5-phenyl oxazoles as starting materials for antidiabetic compounds. WO publication No. 517,591, published December 9, 1992, describes bis(halophenyl)oxazole derivatives as starting materials for the preparation of antiinflammatory agents.

N. Meanwell et al [*J.Med.Chem.*, 35, 3498 (1992)] describe bis(substitutedphenyl)oxazoles as having ADP-induced platelet aggregation inhibition activity.

U.S. Patent No. 4,812,470, to N. Rogers et al, describes phenyl substituted oxazoles as having antibacterial activity.

5

U.S. Patent No. 3,901,908, to K. Fitzi and R. Pfister, describes 2-alkyl and 2-cycloalkyl-4,5-phenyloxazoles as intermediates in the synthesis of imidazoles having analgesic and antipyretic activity.

Specifically, 2-tert-butyl-4-(4-methylsulfonylphenyl)-5-phenyloxazole is described.

10

U.S. Patent No. 4,632,930, to Carini et al, describes antihypertensive alkyl and aryl substituted imidazole, thiazole and oxazole derivatives. Specifically, 5-phenyl-4-(4-methylsulfonylphenyl)- α,α -bis(trifluoromethyl)thiazole-2-methanol is described.

15

R. Cremylin et al describe the synthesis of heterocyclic sulfonyl derivatives and specifically, 4',4''-(2-methyl-4,5-oxazoldiyl)-bis-benzenesulfonamide (*J. Heterocycl.Chem.*, 22, 1211 (1985)).

20

25


T. van Es and O.G.Backeberg [*J.Chem.Soc.*, 1363 (1963)] describe the synthesis of 2-methyl-4,5-substitutedphenyloxazoles, and specifically, 4-[5-(4-chlorophenyl)-2-methyl-4-oxazolyl]benzenesulfonamide.

30

DESCRIPTION OF THE INVENTION

A class of substituted oxazolyl compounds useful in treating inflammation-related disorders is defined by

5 Formula I:



I

wherein R is selected from hydrido, alkyl,
 10 hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl,
 alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl,
 aryl optionally substituted at a substitutable
 position by carboxy, alkyl, alkoxy and halo,
 heteroaryl optionally substituted at a substitutable
 15 position by carboxy, alkyl, alkoxy and halo, aralkyl
 optionally substituted at a substitutable position on
 the aryl radical by carboxy, alkyl, alkoxy and halo,
 aryloxyalkyl optionally substituted at a
 substitutable position with halo, carboxy, alkyl and
 20 alkoxy, aralkoxyalkyl optionally substituted at a
 substitutable position with halo, carboxy, alkyl and
 alkoxy, heteroaryloxyalkyl optionally substituted at
 a substitutable position with halo, carboxy, alkyl
 and alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl,
 25 carboxy, carboxyalkyl, arylthioalkyl,
 aminocarbonylalkyl, N-alkylaminocarbonylalkyl and
 N,N-dialkylaminocarbonylalkyl;

wherein R¹ is selected from cycloalkyl,
 cycloalkenyl, aryl and heteroaryl, wherein R¹ is
 30 optionally substituted at a substitutable position by
 alkyl, alkoxy and halo; and

wherein R² is selected from alkyl, haloalkyl and amino;

or a pharmaceutically-acceptable salt thereof; provided R is not methyl when R² is amino;
5 and further provided that R¹ is not phenyl when R² is methyl and R is isopropyl or tert-butyl.

The phrase "further provided", as used in the above description, is intended to mean that the
10 denoted proviso is not to be considered conjunctive with the other provisos.

Compounds of Formula I would be useful for, but not limited to, the treatment of inflammation in a subject,
15 and for treatment of other inflammation-associated disorders, such as, as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever. For example, compounds of Formula I would be useful to treat arthritis, including but not limited to
20 rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis. Such compounds of Formula I would be useful in the treatment of asthma, bronchitis, menstrual cramps, tendinitis, bursitis, and skin related conditions
25 such as psoriasis, eczema, burns and dermatitis. Compounds of Formula I also would be useful to treat gastrointestinal conditions such as inflammatory bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis and for the prevention of colorectal cancer.
30 Compounds of Formula I would be useful in treating inflammation in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, myasthenia gravis, sarcoidosis,
35 nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, swelling occurring after injury, myocardial ischemia, and the like.

The compounds are useful as anti-inflammatory agents, such as for the treatment of arthritis, with the additional benefit of having significantly less harmful side effects.

5 Preferably, the compounds have a cyclooxygenase II IC₅₀ of less than about 0.1 μ M, and also have a selectivity ratio of cyclooxygenase II inhibition over cyclooxygenase I inhibition of at least 50, and more preferably of at least 100. Even more preferably, the
10 compounds have a cyclooxygenase I IC₅₀ of greater than about 0.5 μ M, and more preferably of greater than 5 μ M. Such preferred selectivity may indicate an ability to reduce the incidence of common NSAID-induced side effects.

15 A preferred class of compounds consists of those compounds of Formula I wherein R is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, lower cycloalkyl,
20 lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl,
25 optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally
30 substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower aralkoxyalkyl
35 optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, carboxy, lower alkoxycarbonyl, lower

alkoxycarbonylalkyl, lower carboxyalkyl, lower arylthioalkyl, lower aminocarbonylalkyl, lower N-alkylaminocarbonylalkyl and lower N,N-dialkylaminocarbonylalkyl;

- 5 wherein R¹ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl and heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, 3,4-methylenedioxyphenyl, indolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; and
- 10 wherein R² is selected from lower alkyl, lower haloalkyl and amino.
- 15

- A class of compounds of particular interest consists of those compounds of Formula I wherein R is selected from hydrido, methyl, ethyl, n-propyl,
- 20 isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,
- 25 difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, hydroxyethenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, hydroxyethynyl, cyclobutyl,
- 30 cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, phenyl and naphthyl; optionally substituted at a substitutable position by fluoro,
- 35 chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyl,

thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, carboxy, acetyl, propanoic, butanoic, pentanoic, hexanoic, phenylthiomethyl, aminocarbonylmethyl, N-methylaminocarbonylmethyl and N,N-dimethylaminocarbonylmethyl;

wherein R¹ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, cyclopentenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-

dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; and

wherein R² is selected from methyl, ethyl, trifluoromethyl, difluoromethyl, fluoromethyl and amino.

10

A family of specific compounds of particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts thereof as follows:

- 15 4-[2-benzyl-5-(phenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-benzyl-5-(4-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
25 4-[2-benzyl-5-(2,5-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2,6-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
30 4-[2-benzyl-5-(3,5-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
35 4-[2-benzyl-5-(3-chlorophenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(2,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 5 4-[2-benzyl-5-(2,5-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(2,6-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 10 4-[2-benzyl-5-(3,5-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(2-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 15 4-[2-benzyl-5-(3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(2,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 20 4-[2-benzyl-5-(2,5-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(2,6-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 25 4-[2-benzyl-5-(3,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3,5-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(2-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 30 4-[2-benzyl-5-(3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 35 4-[2-benzyl-5-(2,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(2,5-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2,6-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(3,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,5-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
10 4-[2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-chloro-2-methylphenyl)oxazol-4-yl]benzenesulfonamide;
15 4-[2-benzyl-5-(2-chloro-6-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-2-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-benzyl-5-(2-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
25 4-[2-benzyl-5-(3-chloro-2-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-chloro-6-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-2-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
30 4-[2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,5-dichloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
35 4-[2-benzyl-5-(2-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(3-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluoro-2-methylphenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(2-fluoro-6-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluoro-2-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
10 4-[2-benzyl-5-(2-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
15 4-[2-benzyl-5-(3-fluoro-2-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-fluoro-6-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluoro-2-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-benzyl-5-(2-thienyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(5-chloro-2-thienyl)oxazol-4-yl]benzenesulfonamide;
25 4-[2-benzyl-5-(cyclohexyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(1-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
30 4-[2-benzyl-5-(3-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
2-benzyl-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-fluorophenyl)oxazole;
35 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluorophenyl)oxazole;

- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,4-difluorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,5-difluorophenyl)oxazole;
5 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,6-difluorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-difluorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,5-difluorophenyl)oxazole;
10 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-chlorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chlorophenyl)oxazole;
15 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chlorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,4-dichlorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,5-dichlorophenyl)oxazole;
20 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,6-dichlorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dichlorophenyl)oxazole;
25 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,5-dichlorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-methoxyphenyl)oxazole;
30 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,4-dimethoxyphenyl)oxazole;
35 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,5-dimethoxyphenyl)oxazole;

- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,6-dimethoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dimethoxyphenyl)oxazole;
5 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,5-dimethoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-methylphenyl)oxazole;
10 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,4-dimethylphenyl)oxazole;
15 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,5-dimethylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2,6-dimethylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dimethylphenyl)oxazole;
20 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,5-dimethylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-chloro-4-methylphenyl)oxazole;
25 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-4-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-2-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-chloro-6-methylphenyl)oxazole;
30 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-2-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-3-methylphenyl)oxazole;
35 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-chloro-4-methoxyphenyl)oxazole;

- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-4-methoxyphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-2-methoxyphenyl)oxazole;
- 5 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-chloro-6-methoxyphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-2-methoxyphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-3-methoxyphenyl)oxazole;
- 10 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,5-dichloro-4-methoxyphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-fluoro-4-methylphenyl)oxazole;
- 15 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-4-methylphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-2-methylphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-fluoro-6-methylphenyl)oxazole;
- 20 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-fluoro-2-methylphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-fluoro-3-methylphenyl)oxazole;
- 25 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-fluoro-4-methoxyphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-4-methoxyphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-2-methoxyphenyl)oxazole;
- 30 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-fluoro-6-methoxyphenyl)oxazole;
- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-fluoro-2-methoxyphenyl)oxazole;
- 35 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-thienyl)oxazole;

- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(5-chloro-2-thienyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(cyclohexyl)oxazole-;
5 2-benzyl-4-(4-methylsulfonylphenyl)-5-(1-cyclohexenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-cyclohexenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-cyclohexenyl)oxazole;
10 2-(ethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(trifluoromethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
15 2-(difluoromethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(hydroxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(carboxy)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
20 2-(methoxycarbonyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(ethoxycarbonyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
25 2-(propyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(benzyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(phenylthiomethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
30 2-(phenoxyethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((4-chlorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
35 2-((3-chlorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;

- 2-((2-chlorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((4-fluorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
5 2-((3-fluorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((2-fluorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
10 2-((4-carboxyphenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((3-carboxyphenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((2-carboxyphenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
15 2-(2-phenethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(3-phenpropyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(carboxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
20 2-(ethoxycarbonylmethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(methoxycarbonylmethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
25 2-(2-carboxyethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(2-methoxycarbonylethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(2-ethoxycarbonylethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
30 2-(3-carboxypropyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(3-methoxycarbonylpropyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
35 2-(3-ethoxycarbonylpropyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;

- 2-(2-quiniolyloxymethyl)-4-(4-methylsulfonylphenyl)-
5-phenyloxazole;
4-[2-(ethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-5-phenyloxazol-4-
5 yl]benzenesulfonamide;
4-[2-(difluoromethyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-(hydroxymethyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
10 4-[2-(carboxy)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-(ethoxycarbonyl)-5-phenyloxazol-4-
15 yl]benzenesulfonamide;
4-[2-(propyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-(benzyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
20 4-[2-(phenylthiomethyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-(phenoxyethyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-((4-chlorophenoxy)methyl)-5-phenyloxazol-4-
25 yl]benzenesulfonamide;
4-[2-((3-chlorophenoxy)methyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-((2-chlorophenoxy)methyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
30 4-[2-((4-fluorophenoxy)methyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-((3-fluorophenoxy)methyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;
4-[2-((2-fluorophenoxy)methyl)-5-phenyloxazol-4-
35 yl]benzenesulfonamide;
4-[2-((4-carboxyphenoxy)methyl)-5-phenyloxazol-4-
yl]benzenesulfonamide;

- 4-[2-((3-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((2-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
5 4-[2-(2-phenylethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(3-phenylpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(carboxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
10 4-[2-(ethoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
15 4-[2-(2-carboxyethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(2-methoxycarbonylethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(2-ethoxycarbonylethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
20 4-[2-(3-carboxypropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(3-methoxycarbonylpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
25 4-[2-(3-ethoxycarbonylpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(2-quiniolyloxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(2-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(2,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(2,5-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2,6-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(3,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,5-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[2-benzyl-4-(3-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(2,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2,5-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2,6-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(3,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,5-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(2-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(2,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2,5-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(2,6-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(3,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,5-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(2-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[2-benzyl-4-(2,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2,5-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(2,6-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,5-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(2-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(3-chloro-2-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2-chloro-6-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chloro-2-methylphenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(4-chloro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(3-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(3-chloro-2-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(2-chloro-6-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 5 4-[2-benzyl-4-(4-chloro-2-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 10 4-[2-benzyl-4-(3,5-dichloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(2-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(3-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
- 15 4-[2-benzyl-4-(3-fluoro-2-methylphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(2-fluoro-6-methylphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(4-fluoro-2-methylphenyl)oxazol-5-yl]benzenesulfonamide;
- 20 4-[2-benzyl-4-(4-fluoro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(2-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 25 4-[2-benzyl-4-(3-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(3-fluoro-2-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(2-fluoro-6-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 30 4-[2-benzyl-4-(4-fluoro-2-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(2-thienyl)oxazol-5-yl]benzenesulfonamide;
- 35 4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(cyclohexyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(1-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(2-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
2-benzyl-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
10 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-fluorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,4-difluorophenyl)oxazole;
15 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,5-difluorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,6-difluorophenyl)oxazole;
20 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-difluorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,5-difluorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
25 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chlorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
30 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,4-dichlorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,5-dichlorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,6-dichlorophenyl)oxazole;
35 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dichlorophenyl)oxazole;

- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,5-dichlorophenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-methoxyphenyl)oxazole;
- 5 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-methoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-methoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,4-dimethoxyphenyl)oxazole;
- 10 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,5-dimethoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,6-dimethoxyphenyl)oxazole;
- 15 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dimethoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,5-dimethoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-methylphenyl)oxazole;
- 20 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-methylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-methylphenyl)oxazole;
- 25 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,4-dimethylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,5-dimethylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2,6-dimethylphenyl)oxazole;
- 30 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dimethylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,5-dimethylphenyl)oxazole;
- 35 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-chloro-4-methylphenyl)oxazole;

- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-4-methylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-2-methylphenyl)oxazole;
- 5 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-chloro-6-methylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-2-methylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-3-methylphenyl)oxazole;
- 10 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-chloro-4-methoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-4-methoxyphenyl)oxazole;
- 15 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-2-methoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-chloro-6-methoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-2-methoxyphenyl)oxazole;
- 20 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-3-methoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,5-dichloro-4-methoxyphenyl)oxazole;
- 25 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-fluoro-4-methylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-4-methylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-2-methylphenyl)oxazole;
- 30 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-fluoro-6-methylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-fluoro-2-methylphenyl)oxazole;
- 35 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-fluoro-3-methylphenyl)oxazole;

- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-fluoro-4-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-4-methoxyphenyl)oxazole;
5 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-2-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-fluoro-6-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-fluoro-2-methoxyphenyl)oxazole;
10 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-thienyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(5-chloro-2-thienyl)oxazole;
15 2-benzyl-5-(4-methylsulfonylphenyl)-4-(cyclohexyl)oxazole-;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(1-cyclohexenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-cyclohexenyl)oxazole;
20 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-cyclohexenyl)oxazole;
2-(ethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
25 2-(trifluoromethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(difluoromethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(hydroxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
30 2-(carboxy)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(methoxycarbonyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
35 2-(ethoxycarbonyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;

- 2-(propyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(benzyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
5 2-(phenylthiomethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(phenoxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-((4-chlorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
10 2-((3-chlorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-((2-chlorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
15 2-((4-fluorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-((3-fluorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-((2-fluorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
20 2-((4-carboxyphenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-((3-carboxyphenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
25 2-((2-carboxyphenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(2-phenethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(3-phenpropyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
30 2-(carboxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(ethoxycarbonylmethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
35 2-(methoxycarbonylmethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;

- 2-(2-carboxyethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(2-methoxycarbonylethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 5 2-(2-ethoxycarbonylethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(3-carboxypropyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(3-methoxycarbonylpropyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 10 2-(3-ethoxycarbonylpropyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(2-quinolioloxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 15 4-[2-(ethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(trifluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(difluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 20 4-[2-(hydroxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(carboxy)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(methoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 25 4-[2-(ethoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(propyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 30 4-[2-(benzyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(phenylthiomethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(phenoxyethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 35 4-[2-((4-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;

- 4-[2-((3-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((2-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
5 4-[2-((4-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((3-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((2-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
10 4-[2-((4-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((3-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
15 4-[2-((2-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-phenethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
20 4-[2-(carboxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
25 4-[2-(methoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-carboxyethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-methoxycarbonylethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
30 4-[2-(2-ethoxycarbonylethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(3-carboxypropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
35 4-[2-(3-methoxycarbonylpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;

- 4-[2-(3-ethoxycarbonylpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-quinoliyloxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 5 5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole;
3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid;
methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanate;
- 10 4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole;
- 15 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
2-benzyl-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-(3-phenylpropyl)oxazole;
- 20 4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-propyloxazole;
2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
- 25 4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-5-[4-methylsulfonylphenyl]oxazole
4-(4-fluorophenyl)-2-[(3-methoxyphenyl)methyl]-5-[4-methylsulfonylphenyl]oxazole;
- 30 2-(diphenylmethyl)-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetic acid;
ethyl 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetate;
- 35 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanoic acid;
methyl 3-[4-(4-fluorophenyl)-5-[4-

- methysulfonylphenyl]oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-5-[4-
methysulfonylphenyl]oxazol-2-yl]butanoic acid;
methyl 4-[4-(4-fluorophenyl)-5-[4-methysulfonyl
5 phenyl]oxazol-2-yl]butanate;
3-[4-(4-fluorophenyl)-5-[4-methysulfonyl
phenyl]oxazol-2-yl]propanamide;
ethyl 2-[4-(4-fluorophenyl)-5-[4-(methysulfonyl)
phenyl]oxazol-2-yl]-2-benzyl-acetate;
10 4-(4-fluorophenyl)-2-(cyclohexylethyl)-5-[4-
(methysulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)-5-[4-
(methysulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)-5-[4-
15 (methysulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(pyridyloxymethyl)-5-[4-
(methysulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methysulfonyl)phenyl]-2-
phenoxymethyloxazole;
20 4-(4-fluorophenyl)-2-(2-hydroxyethyl)-5-[4-
(methysulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(hydroxymethyl)-5-[4-
(methysulfonyl)phenyl]oxazole;
4-(cyclohexyl)-2-phenyl-5-[4-
25 (methysulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-benzylloxymethyl-5-[4-
(methysulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-cyclohexyl-5-[4-
(methysulfonyl)phenyl]oxazole; and
30 5-(4-fluorophenyl)-2-phenyl-4-[4-
(methysulfonyl)phenyl]oxazole.

Within Formula I there is a subclass
of compounds of high interest wherein R is selected
35 from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,
cycloalkylalkyl, aryl optionally substituted at a
substitutatable position by carboxy, alkyl, alkoxy and

halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R¹ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R² is methyl; or a pharmaceutically-acceptable salt thereof; provided R¹ is not phenyl when R is isopropyl or tert-butyl.

A more preferred class of compounds of the first subclass wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and

wherein R¹ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.

10

A class of compounds of particular interest consists of those compounds of the first subclass wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl

optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R¹ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo.

A family of specific compounds of particular interest within the first subclass consists of compounds and pharmaceutically-acceptable salts thereof as follows:

5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole;
3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazol-2-yl]propanoic acid;
methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazol-2-yl]propanate;
4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-2-methyl-5-[4-

- methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-
 phenyloxazole;
2-benzyl-4-(4-fluorophenyl)-5-(4-
5 (methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-(3-
 phenylpropyl)oxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-
 propyloxazole;
10 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-
 methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-5-[4-
 methylsulfonylphenyl]oxazole
4-(4-fluorophenyl)-2-[(3-methoxyphenyl)methyl]-5-[4-
15 methylsulfonylphenyl]oxazole;
2-(diphenylmethyl)-4-(4-fluorophenyl)-5-[4-
 methylsulfonylphenyl]oxazole;
2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]
 oxazol-2-yl]acetic acid;
20 ethyl 2-[4-(4-fluorophenyl)-5-[4-
 methylsulfonylphenyl]oxazol-2-yl]acetate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]
 oxazol-2-yl]propanoic acid;
methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonyl
25 phenyl]oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]
 oxazol-2-yl]butanoic acid;
methyl 4-[4-(4-fluorophenyl)-5-(4-methylsulfonyl
 phenyl)oxazol-2-yl]butanate;
30 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]
 oxazol-2-yl]propanamide;
ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)
 phenyl]oxazol-2-yl]-2-benzyl-acetate;
4-(4-fluorophenyl)-2-(cyclohexylethyl)-5-[4-
35 (methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)-5-[4-
 (methylsulfonyl)phenyl]oxazole;

- 4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(pyridyloxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
5 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenoxymethyloxazole;
4-(4-fluorophenyl)-2-(2-hydroxyethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(hydroxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
10 4-(cyclohexyl)-2-phenyl-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-benzyloxymethyl-5-[4-(methylsulfonyl)phenyl]oxazole;
15 4-(4-fluorophenyl)-2-cyclohexyl-5-[4-(methylsulfonyl)phenyl]oxazole; and
5-(4-fluorophenyl)-2-phenyl-4-[4-(methylsulfonyl)phenyl]oxazole.

- 20 Within Formula I there is a second subclass of compounds of high interest wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and
25 halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and
30 alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with
35 halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R¹ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable

position by alkyl, alkoxy and halo; and wherein R² is amino; or a pharmaceutically-acceptable salt or prodrug thereof; provided R is not methyl.

- 5 A more preferred class of compounds of the second subclass consists of those compounds of wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and
10 naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower
15 aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower
20 heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxy-carbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R¹ is selected from lower cycloalkyl, lower
25 cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally
30 substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.

- A class of compounds of particular interest
35 consists of those compounds of the second subclass wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl,

hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, 5 difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and 10 naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and 15 phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally 20 substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by 25 fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, 30 iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, 35 pentanoic, hexanoic and aminocarbonylmethyl; and wherein R¹ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-

cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo.

10

A family of specific compounds of particular interest within the second subclass consists of compounds and pharmaceutically-acceptable salts thereof as follows:

- 15 4-[2-benzyl-5-(phenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-benzyl-5-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
25 4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
30 4-[2-benzyl-5-(3,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
35 4-[2-benzyl-5-(4-chloro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(3,5-dichloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
10 4-[2-benzyl-5-(3-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-thienyl)oxazol-4-yl]benzenesulfonamide;
15 4-[2-benzyl-5-(5-chloro-2-thienyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(cyclohexyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(1-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-(ethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
25 4-[2-(hydroxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(carboxy)-5-phenyloxazol-4-yl]benzenesulfonamide;
30 4-[2-(methoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(ethoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(n-propyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
35 4-[2-(benzyl)-5-phenyloxazol-4-yl]benzenesulfonamide;

- 4-[2-(phenoxyethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-chlorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
5 4-[2-((4-fluorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(2-phenylethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
10 4-[2-(3-phenylpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(carboxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
15 4-[2-(ethoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(2-quinolylloxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
20 4-[2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(3,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(3,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(3-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(4-chloro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,5-dichloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[2-benzyl-4-(4-fluoro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(2-thienyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(cyclohexyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(1-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-(ethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
25 4-[2-(difluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(hydroxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
30 4-[2-(carboxy)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
35 4-[2-(propyl)-4-phenyloxazol-5-yl]benzenesulfonamide;

- 4-[2-(benzyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(phenoxyethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
5 4-[2-((4-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
10 4-[2-(2-phenethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
15 4-[2-(carboxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(methoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
20 4-[2-(2-quinolioloxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[5-(4-fluorophenyl)-2-methyl-oxazol-4-yl]benzenesulfonamide;
25 [5-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)-2-oxazol-2-yl]propanoic acid;
methyl 3-[5-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-2-(2-phenylethyl)-oxazol-5-yl]benzenesulfonamide;
30 4-[4-(4-fluorophenyl)-2-methyloxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-phenyloxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(3-phenylpropyl)oxazol-5-

- yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-propyloxazol-5-yl]benzenesulfonamide;
4-[2-(tert-butyl)-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyloxazol-5-yl]benzenesulfonamide
4-[4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyloxazol-5-yl]benzenesulfonamide;
10 4-[2-diphenylmethyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]acetic acid;
ethyl 2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]acetate;
15 3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanoic acid;
methyl 3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanate;
20 4-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]butanoic acid;
methyl 4-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]butanate;
3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanamide;
25 ethyl 2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]-2-benzyl-acetate;
4-[4-(4-fluorophenyl)-2-(cyclohexylethyl)oxazol-5-yl]benzenesulfonamide;
30 4-[4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(pyridyloxymethyl)oxazol-5-yl]benzenesulfonamide;
35 4-[4-(4-fluorophenyl)-2-phenoxy-methyloxazol-5-yl]benzenesulfonamide;

- 4-[4-(4-fluorophenyl)-2-(2-hydroxyethyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(hydroxymethyl)oxazol-5-yl]benzenesulfonamide;
5 4-[4-(cyclohexyl)-2-phenyloxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-benzyloxymethyloxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-cyclohexyloxazol-5-yl]benzenesulfonamide; and
10 4-[5-(4-fluorophenyl)-2-phenyloxazol-4-yl]benzenesulfonamide.

Where the term "alkyl" is used, either alone or
15 within other terms such as "haloalkyl", "alkoxyalkyl" and "hydroxyalkyl", embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon
20 atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like. Where the term "alkenyl" is used, it
25 embraces linear or branched carbon carbon double bond-containing radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkenyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Suitable "lower
30 alkenyl" may be a straight or branched one such as vinyl, allyl, isopropenyl, 1- or 2-propenyl, 1-, 2- or 3-butenyl, pentenyl or the like. The term "alkynyl" embraces linear or branched radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms, and
35 containing a carbon-carbon triple bond. The more preferred "lower alkynyl" are radicals having two to ten carbons. Examples of such radicals include ethynyl, 1- or 2-

propynyl, 1-, 2- or 3-butyryl and the like and isomers thereof. The term "hydrido" denotes a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH₂-) radical. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either a bromo, chloro or a fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about twelve carbon atoms any one of which may be substituted with one or more hydroxyl radicals. The term "hydroxyalkenyl" embraces linear or branched alkenyl radicals having two to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. The term "hydroxyalkynyl" embraces linear or branched alkynyl radicals having two to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about twelve carbon atoms, such as methoxy radical. The term "alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or haloalkoxyalkyl radicals. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl and biphenyl. Preferred aryl radicals are those consisting of one, two, or three benzene rings. The term "heteroaryl"

embraces radicals having an unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl

5 [e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.] tetrazolyl [e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.], etc.; unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyll, benzimidazolyl, quinolyl,

10 isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1,5-b]pyridazinyl, etc.], etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic

15 group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl,

20 etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl, etc.]; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example,

25 thiazolyl, thiadiazolyl [e.g., 1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl, etc.] and the like. The term "aralkyl"

30 embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenethyl, and diphenethyl. The terms benzyl and phenylmethyl are interchangeable. The term "aryloxy" embrace oxy-containing aryl radicals attached through an oxygen atom to other

35 radicals. More preferred aryloxy radicals are "lower aryloxy" radicals having a phenyl radical. An example of such radicals is phenoxy. The term "aryloxyalkyl" embraces

alkyl radicals having one or more aryloxy radicals attached to the alkyl radical, that is, to form monoaryloxyalkyl and diaryloxyalkyl radicals. The "aryloxy" or "aryloxyalkyl" radicals may be further substituted to provide

5 haloaryloxyalkyl radicals alkylaryloxy radicals, and the like. Examples of such radicals include chlorophenoxy and methylphenoxy. The term "aralkyloxy" embrace oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. The term "aralkyloxyalkyl" embraces alkyl

10 radicals having one or more aralkyloxy radicals attached to the alkyl radical, that is, to form monoaralkyloxyalkyl and diaralkyloxyalkyl radicals. The "aralkyloxy" or "aralkyloxyalkyl" radicals may be further substituted on the aryl ring portion of the radical. The term

15 "heteroaryloxyalkyl" embraces alkyl radicals having one or more heteroaryloxy radicals attached to the alkyl radical, that is, to form monoheteroaryloxyalkyl and diheteroaryloxyalkyl radicals. The "heteroaryloxy" radicals may be further substituted on the heteroaryl ring portion

20 of the radical. The term "arylthio" embraces radicals containing an aryl radical, as described above, attached to a divalent sulfur atom, such as a phenylthio radical. The term "arylthioalkyl" embraces alkyl radicals substituted with one or more arylthio radicals, as described above.

25 The term "cycloalkyl" embraces radicals having three to ten carbon atoms, such as cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term "cycloalkylalkyl" embraces alkyl radicals substituted with cycloalkyl radicals having three to ten carbon atoms, such as

30 cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl and cycloheptylmethyl. The term "cycloalkenyl" embraces unsaturated radicals having three to ten carbon atoms, such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl

35 and cycloheptenyl. The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals $-SO_2-$. "Alkylsulfonyl"

embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl" denote a sulfonyl radical substituted with an amine radical, forming a sulfonamide ($-\text{SO}_2\text{NH}_2$). The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes $-\text{CO}_2\text{H}$. The terms "carboxyalkyl" and "alkanoyl" embrace radicals having a carboxy radical as defined above, attached to an alkyl radical, which may be substituted or unsubstituted. Examples of such radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl or the like, in which the preferable one is formyl, acetyl, propionyl or trifluoroacetyl. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a "carbonyl" ($-\text{C}=\text{O}$) radical. Examples of such "alkoxycarbonyl" ester radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The term "alkoxycarbonylalkyl" embraces alkyl radicals having one or more alkoxycarbonyl radicals attached to the alkyl radical. The term "aminocarbonylalkyl" embraces alkyl radicals having one or more aminocarbonyl radicals attached to the alkyl radical. The term "alkylaminocarbonylalkyl" embraces alkyl radicals having aminocarbonyl radicals substituted with one or two alkyl radicals. Examples of such include N-alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl radicals such as N-methylaminocarbonylmethyl and N,N-dimethylaminocarbonylmethyl.

The present invention comprises a pharmaceutical composition for the treatment of inflammation and inflammation-associated disorders, such as arthritis,

comprising a therapeutically-effective amount of a compound of Formula I in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

5 The present invention also comprises a therapeutic method of treating inflammation or inflammation-associated disorders in a subject, the method comprising administering to a subject having such inflammation or disorder a therapeutically-effective amount
10 of a compound of Formula I.

Also included in the family of compounds of Formula I are isomeric forms including and the pharmaceutically-acceptable salts thereof. The term
15 "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of
20 compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic,
25 cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propanoic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic,
30 benzoic, anthranilic, mesylic, salicylic, salicylic, *p*-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, β -
35 hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made

from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I.

The compounds of the present invention may contain prodrugs of compounds of the current invention. The term "prodrug" embraces compounds which are metabolized in vivo into compounds of the invention.

The compounds of the present invention may contain asymmetric carbon atoms, and, therefore, the instant invention may also include the individual diastereomers and enantiomers, which may be prepared or isolated by methods known to those skilled in the art.

In other words, any resulting racemate can be resolved into the optical antipodes by known methods, for example, by separation of the diastereomeric salts thereof, with an optically active acid, and liberating the optically active amine compound by treatment with a base. Racemic compounds of the present invention can thus be resolved into their optical antipodes e.g., by fractional crystallization of d- or l-(tartrates, mandelates, or camphorsulfonate) salts.

Additional methods for resolving optical isomers, known to those skilled in the art may be used, for example, those discussed by J. Jaques et al in Enantiomers, Racemates, and Resolutions, John Wiley and Sons, New York (1981).


Compounds of the present invention also are meant to include, where possible, hydrated species.

5

GENERAL SYNTHETIC PROCEDURES

The compounds of the invention can be synthesized according to the following procedures of Schemes I-VIII, wherein the R-R² substituents are as
10 defined for Formula I, above, except where further noted.

Scheme I




15

Synthetic Scheme I shows the four step procedure which can be used to prepare the substituted ketone compounds 4 from the substituted benzaldehyde 1 and acid 2, where R² is alkyl. In step one, benzaldehyde 1 and substituted acetic acid 2 are
20 first heated in acetic anhydride and triethylamine via a Perkin condensation. In step two, hydrolysis produces the corresponding 2,3-disubstituted acrylic

acids 3. In step three, the acrylic acids 3 are reacted with diphenylphosphorylazide (DPPA) and triethylamine in toluene at 0°C and then warmed to room temperature to form acylazides. In step four, the crude acylazides are heated to form an isocyanate via a Curtius rearrangement. The isocyanate is trapped as the N-*t*-butyloxycarbonyl enamine derivative via the addition of *tert*-butanol. Acidic hydrolysis, such as by using concentrated HCl, provides the substituted ketone 4 intermediates.

Scheme II



15


Synthetic Scheme II shows an alternative approach which can be used to prepare substituted ketone intermediates 7, isomers of 4 where R² is alkyl, via the use of Friedel-Crafts acylation. An acylating agent 5, such as an acid chloride, is treated with aluminum chloride in an inert solvent, such as methylene chloride, chloroform, nitrobenzene, dichlorobenzene or chlorobenzene, and reacted with alkylthiobenzene 6 to form ketone 7.

25

Other synthetic approaches are possible to form the desired ketones. These alternatives include reacting appropriate Grignard or lithium reagents with substituted acetic acids or corresponding esters.

30

Scheme III




- 5 TBSCl is tert-butyl-dimethylsilyl chloride
 MCPBA is *m*-chloroperoxybenzoic acid.

Scheme III shows the five step synthesis,
 as described in U.S. Patent No. 3,647,858, which can
 10 be used to prepare the 5-(4-alkylsulfonylphenyl)
 oxazoles 12 of Formula I from ketone 4 (prepared in
 Scheme I). Preparation of the silyl enol ether 8 is
 followed by oxidation, such as with *m*-
 chloroperoxybenzoic acid, to give the appropriate
 15 silylated benzoin 9. Desilylation of this silylated
 benzoin 9 is achieved using aqueous acid, such as
 trifluoroacetic acid, to give the desired benzoin 10.
 Reaction of the benzoin 10 with the appropriate acid

chloride in the presence of base, such as pyridine, gives the benzoin esters 11 which may be converted to the antiinflammatory oxazoles 12 of the present invention upon treatment with ammonium acetate in acetic acid at reflux.

Scheme IV




10

Scheme IV shows the five step synthesis, similar to that described above in Scheme III, which can be used to prepare the 4-(4-alkylsulfonylphenyl) oxazoles 17 of Formula I from ketone 7 (prepared in Scheme II). Preparation of the silyl enol ether 13 is followed by oxidation, such as with *m*-chloroperbenzoic acid, to give the appropriate silylated benzoin 14. Desilylation of this silylated

benzoin **14** is achieved using aqueous acid, such as trifluoroacetic acid to give the desired benzoin **15**. Reaction of the benzoin **15** with the appropriate acid chloride in the presence of base, such as pyridine, gives the benzoin esters **16** which may be converted to the antiinflammatory oxazoles **17** of the present invention upon treatment with ammonium acetate in acetic acid at reflux.

10


Scheme V

Scheme V shows the four step synthesis which can be used to prepare oxazoles **20** from ketones **4** (prepared in Synthetic Scheme I). In step one, ketones **4** are readily brominated via the addition of bromine in acetic acid to form the 2-bromoethanone intermediates. In step two, reaction of the bromoethanone with aqueous acetone yields the benzoin **18**. In step three, reaction of the benzoin **18** with the appropriate acid chloride in the presence of

base, such as pyridine, gives the benzoin esters 19. In step four, benzoin esters 19 are converted to the oxazoles 20 upon treatment with ammonium acetate in acetic acid at reflux.

5

Scheme VI




10

Similarly, Scheme VI shows the four step synthesis which can be used to prepare oxazoles 23 from ketones 7 (prepared in Synthetic Scheme II). In step one, ketones 7 are readily brominated via the addition of bromine in acetic acid to form the 2-bromoethanone intermediates. In step two, reaction of the bromoethanone with aqueous acetone yields the benzoin 21. In step three, reaction of the benzoin 21 with the appropriate acid chloride in the presence of base, such as pyridine, gives the benzoin esters 22. In step four, benzoin esters 22 are converted to the oxazoles 23 upon treatment with ammonium acetate in acetic acid at reflux.

20

Scheme VII




5

An alternative synthesis of the alkylsulfonylphenyloxazoles 12 and 17 is accomplished as shown in Synthetic Scheme VII from oxazoles 20 and 23 (prepared in Schemes V and VI). Oxazoles 20 and 23, where R² is an alkyl radical, are oxidized, such as with MCPBA (2 equivalents) in methylene chloride to form the antiinflammatory alkylsulfonyl oxazoles 12 and 17. Other suitable oxidizing agents include Oxone®, hydrogen peroxide, periodate, peracetic acid and the like.

10

15

Scheme VIII




5 Synthetic Scheme VIII shows the three step
procedure used to prepare sulfonamide
antiinflammatory agents 25 from their corresponding
methyl sulfones 24. In step one, a THF solution of
the methyl sulfones 24 at -78°C is treated with an
10 alkyl lithium reagent, e.g., methyl lithium, n-
butyllithium, etc. In step two, the anions generated
in step one are treated with an organoborane, e.g.,
triethylborane, tributylborane, etc., at -78°C then
allowed to warm to ambient temperature prior to
15 stirring at reflux. In step three, an aqueous
solution of sodium acetate and hydroxylamine-O-
sulfonic acid is added to provide the corresponding
sulfonamide antiinflammatory agents 25 of this
invention.

20

The following examples contain detailed
descriptions of the methods of preparation of
compounds of Formula I. These detailed descriptions
fall within the scope, and serve to exemplify, the
25 above described General Synthetic Procedures which
form part of the invention. These detailed
descriptions are presented for illustrative purposes
only and are not intended as a restriction on the
scope of the invention. All parts are by weight and
30 temperatures are in Degrees centigrade unless
otherwise indicated.

EXAMPLE 1



5

4-(4-Fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole

10 Step 1: Preparation of 1-(4-fluorophenyl)-2-hydroxy-2-(methylsulfonyl)phenyl ethanone

A suspension of 2.03 g sodium hydride in 125 mL tetrahydrofuran (THF) was stirred at 0°C under a nitrogen atmosphere as a solution containing 20.0 g of 1-(4-fluorophenyl)-2-[4-(methylthio)phenyl]ethanone, as prepared in U.S. Patent No. 3,647,858, in 100 mL of THF was added dropwise over 30 minutes. The reaction was allowed to warm to 25°C for 18 hours. A solution containing 12.7 g (84.5 mmol) of *tert*-butyl-dimethylsilyl chloride (DBSCL) in 20 mL THF was added over 5 minutes and the resulting solution stirred at 25°C for 18 hours. The reaction was quenched by pouring into aqueous sodium bicarbonate. The mixture was extracted with ethyl acetate and the combined organic extracts dried over sodium sulfate. Concentration in vacuo provides a yellow oil, which solidified on standing to give 27.9 g of the silyl enol ether. NMR spectra was consistent with the assigned structure.

The silyl enol ether was used without further purification.

5 A solution containing 27.9 g of the silyl enol ether in 500 mL methylene chloride (CH_2Cl_2) was cooled to 0°C under a nitrogen atmosphere while being stirred mechanically. 77.1g of *m*-chloroperoxybenzoic acid (technical grade, 50-60%) was added and the reaction was stirred at 0°C for 2 hours and allowed
10 to warm to 25°C over 1 hour. The reaction mixture was washed with an aqueous solution of sodium metabisulfite, followed by aqueous sodium bicarbonate. The organic solution was dried over sodium sulfate and concentrated in vacuo to give 24.5
15 g of 1-(4-fluorophenyl)-2-tert-butyldimethylsilyloxy-2-[4-(methylsulfonyl)phenyl]ethanone. NMR spectra were consistent with the assigned structure. This material was used without further purification.

20 The benzoin silyl ether was dissolved in 100 mL of 90% aqueous trifluoroacetic acid and stirred at 25°C for 18 hours. The reaction was quenched by slowly pouring into saturated aqueous sodium bicarbonate solution. The product was
25 extracted with ethyl acetate and the combined organic extracts were dried over sodium sulfate. Concentration in vacuo provided an oily solid, which was recrystallized from 50% ethyl acetate/isooctane to give 15.5 g of a crystalline white solid (mp 122-
30 123°C) whose structure was assigned as 1-(4-fluorophenyl)-2-hydroxy-2-(methylsulfonyl)phenyl)ethanone on the basis of its spectral properties.

35 The isomeric benzoin, 2-(4-fluorophenyl)-2-hydroxy-1-(4-(methylsulfonyl)phenyl)ethanone, was

prepared analogously from 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl] ethanone.


5 Step 2: Preparation of 4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole.

10 A solution containing 5.00 g of 1-(4-fluorophenyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethanone in 100 mL methylene chloride (CH₂Cl₂) was stirred at 25°C as 6.60 mL of pyridine was added, followed by 3.61 mL of hydrocinnamoyl chloride.

15 The reaction was stirred at 25°C for 48 hours, after which the organic solution was washed with 1N HCl, dried over sodium sulfate and concentrated in vacuo to give an oily solid. This material was recrystallized from 50% ethyl
20 acetate/isooctane to give 4.40 g of a beige crystalline solid (mp 152-153.5°C). NMR spectra were consistent with the assigned structure of 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-2-(2-phenyl)propionyloxy ethanone. This material was
25 dissolved in 100 mL of glacial acetic acid and 7.70 g of ammonium acetate was added. The reaction was heated to reflux with stirring for 1.5 hours, after which it was cooled to room temperature and poured into 100 mL of water. The product was extracted with
30 ethyl acetate and the combined organic extracts washed with aqueous sodium bicarbonate, dried over sodium sulfate and concentrated in vacuo to give an oily solid which was recrystallized from 50% ethyl acetate/isooctane to give 3.55 g of 4-(4-
35 fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole as a white crystalline solid (mp 117-

118°C). NMR spectra was consistent with the assigned structure.


EXAMPLE 2



4-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole

10 4-(4-Fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole was prepared in an analogous manner from 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]ethanone. Melting point: 158-159°C.


EXAMPLE 3



4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole


25 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole was prepared in a manner analogous to Example 1. Melting point: 204-205°C.

65

EXAMPLE 4

5 **2-Benzyl-4-(4-fluorophenyl)-5-(4-**
 (methylsulfonyl)phenyloxazole


 2-Benzyl-4-(4-fluorophenyl)-5-(4-
 (methylsulfonyl)phenyloxazole was prepared in a
 10 manner analogous to Example 1. The m/z 408 (M+H)⁺
 was consistent with the assigned structure.

EXAMPLE 5

15

4-(4-Fluorophenyl)-5-[4-methylsulfonylphenyl]-
2-(3-phenylpropyl)oxazole

20 4-(4-Fluorophenyl)-5-[4-methylsulfonyl
 phenyl]-2-(3-phenylpropyl)oxazole was prepared in a
 manner analogous to Example 1. The m/z 436 (M+H)⁺
 was consistent with the assigned structure.

EXAMPLE 6


5

**4-(4-Fluorophenyl)-5-[4-methylsulfonylphenyl]-
2-propyloxazole**

4-(4-Fluorophenyl)-5-[4-methylsulfonyl
phenyl]-2-propyloxazole was prepared in a manner
analogous to Example 1. The m/z 360 $(M+H)^+$ was
consistent with the assigned structure.

EXAMPLE 7

15




**2-(Tert-butyl)-4-(4-fluorophenyl)-5-[4-
(methylsulfonyl)phenyl]oxazole**

20


2-(Tert-butyl)-4-(4-fluorophenyl)-5-[4-
(methylsulfonyl)phenyl]oxazole was prepared in a
manner analogous to Example 1. Melting point: 130-
131°C.

25

EXAMPLE 8

5 **4-(4-Fluorophenyl)-2-(4-methoxyphenyl)methyl-**
 5-[4-methylsulfonylphenyl]oxazole

4-(4-Fluorophenyl)-2-(4-methoxyphenyl)methyl-
 5-[4-methylsulfonylphenyl]oxazole was prepared in a
 10 manner analogous to Example 1. Melting point: 123-
 124°C.


EXAMPLE 9

15

4-(4-Fluorophenyl)-2-(3-methoxyphenyl)methyl-
5-[4-methylsulfonylphenyl]oxazole


20 4-(4-Fluorophenyl)-2-(3-methoxyphenyl)methyl-
 5-[4-methylsulfonylphenyl]oxazole was prepared in a
 manner analogous to Example 1. The m/z 437 (M+H)⁺
 was consistent with the assigned structure.

68

EXAMPLE 10

5 **2-Diphenylmethyl-4-(4-fluorophenyl)-**
 5-[4-methylsulfonylphenyl]oxazole


2-Diphenylmethyl-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole was prepared in a manner
10 analogous to Example 1. Melting point: 155-156°C.

EXAMPLE 11

15


Ethyl 2-[4-(4-fluorophenyl)-5-(4-
 methylsulfonylphenyl)oxazol-2-yl]acetate

Ethyl 2-[4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)oxazol-2-yl]acetate was prepared
20 in a manner analogous to Example 1. Melting point:
123-124°C.

EXAMPLE 12


5 **Methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanate**

 Methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanate was prepared in a manner analogous to Example 1. The m/z 404 (M+H)⁺ was consistent with the assigned structure.

EXAMPLE 13

15 **Methyl 4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanate**

20 Methyl 4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanate was prepared in a manner analogous to Example 1. Melting point: 89-91°C.

EXAMPLE 14


5

5-(4-Fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole

5-(4-Fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole was prepared in a manner analogous to Example 1. The m/z 332 (M+H)⁺ was consistent with the assigned structure.

EXAMPLE 15

15



Methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoate

20


Methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoate was prepared in a manner analogous to Example 1. The m/z

71

404 (M+H)⁺ was consistent with the assigned structure.

EXAMPLE 16

5




10

2-[4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]
oxazol-2-yl]acetic acid

2-[4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid was prepared from Example 11 via alkaline hydrolysis using 1 N sodium hydroxide in methanol and appropriate reaction conditions. Melting point: 118-120°C.

15


EXAMPLE 17



5 3-[4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid

3-[4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid was prepared from Example 12 in a manner analogous to Example 17. Melting point: 197-198°C. The m/z 390 (M+H)⁺ was consistent with the assigned structure.

15 **EXAMPLE 18**




20 4-[4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]butanoic acid

73

4-[4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]butanoic acid was prepared from Example 13 in a manner analogous to Example 17. Melting point: 140-141°C. The m/z 404 (M+H)⁺ was

5 consistent with the assigned structure.

EXAMPLE 19



10


3-[5-(4-Fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid

15

3-[5-(4-Fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid was prepared from Example 15 in a manner analogous to Example 17. The m/z 390 (M+H)⁺ was consistent with the assigned structure.

20

EXAMPLE 20




5 4-(4-Fluorophenyl)-2-(3-hydroxypropyl)-5-[4-
 (methylsulfonyl)phenyl]oxazole

A solution containing 100 mg (0.239 mmol)
of 3-[4-(4-fluorophenyl)-5-[4-
10 (methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid,
methyl ester in 10 mL of tetrahydrofuran was cooled
to 0°C with stirring under a nitrogen atmosphere as
0.53 mL of diisobutylaluminum hydride (1M in toluene,
0.523 mmol) was added dropwise over 5 minutes. The
15 reaction was allowed to warm to 25°C and poured into
100 mL of a saturated solution of sodium potassium
tartarate. Ethyl acetate (100 mL) was added and the
mixture was stirred until the layers separated
(approx. 1 hour). The organic layer was separated
20 and dried over sodium sulfate. Concentration in
vacuo gave an oily solid, which was recrystallized
from 50 % ethyl acetate-isooctane to give 75 mg of a
white crystalline solid (mp 123-124°C) which was
characterized on the basis of its spectral
25 characteristics: ¹H-NMR (CDCl₃, 300 MHz) δ 2.10 (m,
2H), 2.56 (bs, 1H), 3.01 (t, 2H, J=7.0 Hz), 3.07 (s,
3H); 3.80 (t, 2H, J=5.9 Hz), 7.09 (t, 2H, J=8.5 Hz),
7.57 (dd, 2H, J=8.5 and 5.5 Hz), 7.73 (d, 2H, J=8.5

75


Hz) and 7.89 (d, 2H, J=8.5 Hz). ^{19}F -NMR (CDCl_3 , 280 MHz) δ -111.97. LRMS m/z 376 (M + H) $^+$. HRMS calc. for $\text{C}_{19}\text{H}_{18}\text{NO}_4\text{FS}$: 376.1019. Observed: 376.1026. Analysis calc. for $\text{C}_{19}\text{H}_{18}\text{NO}_4\text{FS-C}$: 60.79, H: 4.83, N: 5 3.73. Observed-C: 60.53, H: 4.85, N: 3.66.

EXAMPLE 21

5 3-[4-(4-Fluorophenyl)-5-(4-
 (methylsulfonyl)phenyl)
 oxazol-2-yl]propanamide

 3-[4-(4-fluorophenyl)-5-(4-(methylsulfonyl)
10 phenyl)oxazol-2-yl]propanamide was prepared by
treating methyl 3-[4-(4-fluorophenyl)-5-(4-
(methylsulfonyl)phenyl)oxazol-2-yl]propanoic acid,
(Example 12) with excess ammonia in methanol for 5
days. Melting point: 193-195°C.

15

EXAMPLE 22

20

5-(4-Fluorophenyl)-2-phenyl-4-[4-
(methylsulfonyl)phenyl]oxazole

Step 1: Preparation of 5-(4-Fluorophenyl)-4-[4-(methylthio)phenyl]-2-phenyloxazole

A solution containing 560 mg (2.03 mmol) of
5 2-(4-fluorophenyl)-2-hydroxy-1-[4-(methylthio)phenyl]
ethanone in 50 mL of methylene chloride was stirred at
25°C as 0.82 mL (10.15 mmol) of pyridine was added,
followed by 0.28 mL (2.44 mmol) of benzoyl chloride.
The reaction was stirred at 25°C for 2 days, after
10 which it was washed with 1N HCl, dried over sodium
sulfate and concentrated in vacuo to give a crude oil
which was characterized as the benzoin ester on the
basis of its spectral characteristics: ¹H-NMR (CDCl₃,
300 MHz) δ 2.53 (s, 3H), 7.08 (s, 1H), 7.12 (t, 2H,
15 J=8.7 Hz), 7.27 (d, 2H, J=8.7 Hz), 7.49 (t, 2H, J=7.7
Hz), 7.60 (m, 3H), 7.94 (d, 2H, J=8.7 Hz) and 8.14 (d,
2H, J=8.7 Hz). This material was dissolved in 50 mL
of glacial acetic acid and 1.56 g (20.3 mmol) of
ammonium acetate was added. The reaction was heated
20 at reflux for 2 hours, cooled to 25°C and poured into
100 mL of water. The aqueous solution was extracted
with ethyl acetate and the combined organic extracts
were washed with water and sodium bicarbonate
solution, dried over sodium sulfate and concentrated
25 in vacuo. The crude solid was purified by flash
chromatography using a silica gel column and 50% ethyl
acetate/hexane as the eluent to give a white solid
which was recrystallized from 50% ethyl
acetate/isooctane to give 450 mg (61%) of a white
30 crystalline solid (mp 118-119°C) whose structure was
assigned as 5-(4-fluorophenyl)-4-[4-(methylthio)
phenyl]-2-phenyl oxazole on the basis of its spectral
characteristics: ¹H-NMR (CDCl₃, 300 MHz) δ 2.52 (s,
3H), 7.10 (t, 2H, J=8.8 Hz), 7.28 (d, 2H, J=8.5 Hz),
35 7.47 (m, 3H), 7.62 (m, 4H) and 8.13 (m, 2H). ¹⁹F-NMR
(CDCl₃, 280 MHz) δ -111.96. LRMS m/z 361 (M)+. HRMS
Calc'd. for C₂₂H₁₆NOFS: 361.0937. Observed: 361.0970.

Analysis Calc'd. for $C_{22}H_{16}NOFS$: C, 71.51; H, 6.55; N, 3.79. Observed: C, 72.85; H, 4.52; N, 3.84.


5 Step 2: Preparation of 5-(4-Fluorophenyl)-4-[4-(methylsulfinyl)phenyl]-2-phenyloxazole.

A solution containing 64 mg (0.173 mmol) of 5-(4-fluorophenyl)-4-[4-(methylthio)phenyl]-2-phenyloxazole in 10 mL of methylene chloride was
10 stirred at $-78^{\circ}C$ as 60 mg (0.173 mmol based on 50% purity) of *m*-chloroperoxybenzoic acid was added all at once. The reaction was stirred at $-78^{\circ}C$ for 1 hour. Thin-layer chromatography (TLC) (silica, 50% hexane-ethyl acetate) indicated that the reaction mixture
15 consisted of mostly sulfoxide, with a minor amount of sulfide and sulfone. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium
20 metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as
25 the eluent. Recrystallization from 50% ethyl acetate/isooctane gave 48 mg (74%) of a white crystalline solid (mp $164-165^{\circ}C$) whose structure was assigned as 5-(4-fluorophenyl)-4-[4-(methylsulfinyl)phenyl]-2-phenyl oxazole on the basis
30 of its spectral characteristics: 1H -NMR ($CDCl_3$, 300 MHz) δ 2.80 (s, 3H), 7.16 (t, 2H, $J=8.5$ Hz), 7.54 (m, 3H), 7.66-7.75 (m, 4H), 7.93 (d, 2H, $J=8.5$ Hz) and 8.19 (m, 2H). LRMS m/z 377 (M)⁺. HRMS Calc'd. for $C_{22}H_{16}NO_2FS$: 377.0886. Observed: 377.0868. Analysis
35 Calc'd. for $C_{22}H_{16}NO_2FS$: C, 70.01; H, 4.27; N, 3.71. Observed: C, 68.18; H, 4.19; N, 3.58.

Step 3: Preparation of 5-(4-Fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-phenyloxazole.


A solution containing 64 mg (0.173 mmol) of
5 5-(4-fluorophenyl)-4-[4-(methylthio)phenyl]-2-phenyloxazole in 10 mL of methylene chloride was stirred at -78 °C as 120 mg (0.346 mmol based on 50% purity) of *m*-chloroperoxybenzoic acid was added all at once. The reaction was stirred at -78 °C for 1 hour
10 and TLC (silica, 50% hexane-ethyl acetate) indicated that the reaction mixture consisted of mostly sulfone. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer
15 was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by flash chromatography on a silica gel
20 column using 50% ethyl acetate/hexane as the eluent. Recrystallization from 50% dichloromethane/isooctane gave 62 mg (91%) of a white crystalline solid (mp 175-176°C) whose structure was assigned as 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-phenyl
25 oxazole on the basis of its spectral characteristics:
¹H-NMR (CDCl₃, 300 MHz) δ 3.13 (s, 3H), 7.19 (t, 2H, J=8.6 Hz), 7.55 (m, 3H), 7.69 (m, 2H), 8.00 (m, 2H), 8.17 (m, 2H). LRMS m/z 393 (M)⁺. HRMS Calc'd. for C₂₂H₁₆NO₃FS: 393.0835. Observed: 393.0865.

80

EXAMPLE 23

5 **4-(4-Fluorophenyl)-2-cyclohexyl-5-[4-(methylsulfonyl)phenyl]oxazole**

4-(4-Fluorophenyl)-2-cyclohexyl-5-[4-(methylsulfonyl)phenyl]oxazole was prepared in a
 10 manner analogous to Example 1. Melting point: 127-128°C.

EXAMPLE 24

15

4-(4-Fluorophenyl)-2-benzyloxymethyl-5-[4-(methylsulfonyl)phenyl]oxazole

20 Step 1: Preparation of the benzoin ester

A solution containing 2.07 g (6.71 mmol) of 1-(4-fluorophenyl)-2-hydroxy-2-[4-(methylsulfonylphenyl)ethanone in 100 mL of methylene


chloride was stirred at 25°C as 2.71 mL (33.55 mmol) of pyridine was added, followed by the addition of 1.27 mL (8.05 mmol) of benzyloxyacetyl chloride. The reaction was stirred at 25°C for 48 hours, after which
5 the resulting yellow solution was washed with 1N HCl, dried over sodium sulfate and concentrated in vacuo. The oily yellow solid was purified via flash chromatography on a silica gel column using 20 % ethyl acetate/hexane as the eluent. This provided 2.22 g
10 (73 %) of a white foam, which was characterized as the benzoin ester on the basis of its NMR spectra: ¹H-NMR (CDCl₃, 300 MHz) δ 3.03 (s, 3H), 4.23 (d, 1H, J=17.0 Hz), 4.33 (d, 1H, J=17.0 Hz), 4.67 (s, 2H), 6.95 (s, 1H), 7.13 (t, 2H, J=8.5 Hz), 7.35 (m, 5H), 7.66 (d, 2H, J=8.1 Hz) and 7.98 (m, 4H). ¹⁹F-NMR (CDCl₃, 280
15 MHz) δ -102.5.

20 Step 2: Preparation of 2-benzyloxymethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole.

A solution containing 2.22 g (4.86 mmol) of the benzoin ester and 3.74 g (48.6 mmol) of ammonium acetate in 100 mL of acetic acid was heated to 80°C
25 for 2 hours. The reaction was cooled to 25°C and poured into water. The product was extracted into ethyl acetate and the combined organic extracts washed with an aqueous solution of sodium bicarbonate. The solution was dried over sodium sulfate and
30 concentrated in vacuo to give a yellow oil. This crude material was purified by flash chromatography on a silica gel column using 25 % ethyl acetate/hexane as the eluent to give 1.92 g (90%) of a clear oil, which was characterized as 2-benzyloxymethyl-4-(4-
35 fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole on the basis of its spectral properties: ¹H-NMR (CDCl₃, 300 MHz) δ 3.07 (s, 3H), 4.70 (s, 2H), 4.72 (s, 2H),

7.11 (t, 2H, J=8.8 Hz), 7.22-7.40 (m, 5H), 7.58 (m, 2H), 7.76 (d, 2H, J=8.8 Hz) and 7.91 (d, 2H, J=8.8 Hz). ^{19}F -NMR (CDCl_3 , 280 MHz) δ -111.88.

5

EXAMPLE 25

10

2-Phenyl-4-(cyclohexyl)-5-[4-(methylsulfonyl)phenyl]oxazole

Step 1: Preparation of 1-(cyclohexyl)-2-hydroxy-2-[4-(methylthiophenyl)ethanone

15

A 250 mL round bottomed flask was equipped with a mechanical stirrer and reflux condenser and charged with 30 mL of absolute ethanol, 3,4-dimethyl-5-(2-hydroxyethyl)thiazolium iodide (2.00 g, 7.0 mmol), 4-methylthiobenzaldehyde (10.66 g, 70.0 mmol),
20 and freshly distilled cyclohexanecarboxaldehyde (7.68 g, 70.1 mmol). The solution was stirred vigorously, treated with triethylamine (4.27 g, 42.2 mmol) and heated to reflux for 24 hours. The solution was treated with additional portions of 3,4-dimethyl-5-(2-
25 hydroxyethyl)thiazolium iodide (2.05 g, 7.01 mmol), triethylamine (4.84 g, 48.0 mmol), and cyclohexanecarboxaldehyde (7.01 g, 62.5 mmol), and heated to reflux for an additional 42 hours. The solution was concentrated in vacuo, the residue
30 dissolved in chloroform, washed with 3 N HCl, saturated aqueous sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to afford 18.75 g, (>100%) of a

yellow oil that solidified upon standing. The crude solid was purified by trituration with ether providing the desired compound in pure form 15.80 g, (86%, mp 110-111.5°C) which was characterized as 1-

- 5 (cyclohexyl)-2-hydroxy-2-[4-(methylthiophenyl)ethanone on the basis of its NMR spectra. ¹H-NMR (CDCl₃, 300 MHz) δ 1.00-1.47 (m, 6H), 1.60-1.95 (m, 4H), 2.45 (m, 1H), 2.52 (s, 3H), 4.38(d, J=3.9 Hz, 1H), 7.55 (d, J=3.9 Hz, 1H), 7.25 (m, 4H). HRMS Calc'd. for
10 C₁₅H₂₀NO₂S: 264.1184. Observed: 264.1207.

Step 2: Preparation of benzoin ester

- A solution containing 162 mg (0.62 mmol) of
15 1-(cyclohexyl)-2-hydroxy-2-[4-(methylthiophenyl)ethanone in 10 mL of methylene chloride was stirred at 25°C as 251 μL (31 mmol) of pyridine was added, followed by the addition of 86 μL (1.24 mmol) of benzoyl chloride. The reaction was stirred at 25°C
20 for 48 hours, after which the resulting yellow solution was washed with 1N HCl, dried over sodium sulfate and concentrated in vacuo. The crude solid was purified via flash chromatography on a silica gel column using 10 % ethyl acetate/hexane as the eluent.
25 This provided 131 mg (57 %) of a white foam, which was characterized as the benzoin ester on the basis of its NMR spectra: ¹H-NMR (CDCl₃, 300 MHz) δ 1.03-1.48 (m, 6H), 1.56-1.88 (m, 3H), 2.03-2.14 (m, 1H), 2.48 (s, 3H), 2.53 (m, 1H), 6.28 (s, 1H), 7.20-7.70 (m, 5H),
30 8.05-8.17 (m, 4H).

Step 3: Preparation of 2-(phenyl)-4-(cyclohexyl)-5-[4-(methylthio)phenyl]oxazole

- 35 A solution containing 131 mg (0.355 mmol) of the benzoin ester and 273 mg (35 mmol) of ammonium acetate in 10 mL of acetic acid was heated to 80°C for


2 hours. The reaction was cooled to 25°C and poured into water. The product was extracted into ethyl acetate and the combined organic extracts washed with an aqueous solution of sodium bicarbonate. The solution was dried over sodium sulfate and concentrated in vacuo to give the crude oxazole. This crude material was purified by crystallization from a mixture of dichloromethane and isooctane to give 89 mg, (72%, mp 151-151.5°C) of material, which was characterized as 2-(phenyl)-4-(cyclohexyl)-5-[4-(methylthio)phenyl]oxazole on the basis of its spectral properties: ¹H-NMR (CDCl₃, 300 MHz) δ 1.30-1.45 (m, 3H), 1.70-1.94 (m, 7H), 2.54 (s, 3H), 2.80-2.90 (m, 1H), 7.34 (d, J=8.5Hz, 2H), 7.42 (m, 3H), 7.55 (d, J=8.5Hz, 2H), 8.08 (d, J=7.7Hz, 2H). HRMS Calc'd. for C₂₂H₂₃NOS (M+H): 350.1579. Observed: 350.1597. The material from this experiment was used directly in the next step without further purification.

20 Step 4: Preparation of 2-phenyl-4-(cyclohexyl)-5-[4-(methylsulfonyl)phenyl]oxazole

A solution of 38 mg (0.11 mmol) of 2-phenyl-4-(cyclohexyl)-5-[4-(methylthio)phenyl]oxazole in 4 mL of methylene chloride was stirred at -78°C as 75 mg (0.22 mmol based on 50% purity) of *m*-chloroperoxybenzoic acid was added all at once. The reaction was stirred at -78°C for 1 hour. Thin-layer chromatography (TLC) (silica, 50% hexane/ethyl acetate) indicated the reaction mixture consisted of mostly sulfone. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by

crystallization from 50% dichloromethane/isooctane gave 26 mg (62%) of pure product, whose structure was assigned as 2-phenyl-4-(cyclohexyl)-5-[4-(methylsulfonyl)phenyl]oxazole on the basis of its spectral characteristics: mp 231°C. ¹H-NMR (CDCl₃, 300 MHz) δ 1.34-1.43 (m, 3H), 1.72-1.95 (m, 7H), 2.84 (m, 1H), 3.10 (s, 3H), 7.47 (m, 3H), 7.82 (d, J=8Hz, 2H), 8.03 (d, J=8Hz, 2H), 8.10 (m, 2H). . LRMS m/z 382 (M)+. HRMS Calc'd. for C₂₂H₂₃NO₃S: 382.1477. Observed: 382.1436. Analysis Calc'd. for C₂₂H₂₃NO₃S: C, 69.27; H, 6.08; N, 3.67. Observed: C, 68.99; H, 6.07; N, 3.63.

EXAMPLE 26



4-(4-Fluorophenyl)-2-(3-hydroxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole


20

To a solution containing 5.0 g (11.4 mmol) of 2-benzyloxymethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole (prepared in Example 24) in 20 mL of 50 % THF-methanol, was added 100 mg of 10% Pd on charcoal in a Fisher-Porter bottle. The reaction vessel was evacuated and then charged with hydrogen at 50 psi for 24 hours. The Pd on carbon was removed by filtration through diatomaceous earth and the filtrate concentrated in vacuo to give 3.8 g.

86

(97 %) of a white crystalline solid (mp 156-157°C)
(recrystallized from 50% ethyl acetate/isooctane)
whose structure was assigned as 4-(4-fluorophenyl)-2-
hydroxymethyl-5-[4-(methylsulfonyl)phenyl]oxazole on
5 the basis of its spectral characteristics: $^1\text{H-NMR}$
(CDCl_3 , 300 MHz) δ 3.07 (s, 3H), 3.21 (bs, 1H), 4.81
(s, 2H), 7.10 (t, 2H, $J=8.5$ Hz), 7.56 (m, 2H), 7.72
(d, 2H, $J=8.8$ Hz) and 7.90 (d, 2H, $J=8.8$ Hz). $^{19}\text{F-NMR}$
(CDCl_3 , 280 MHz) δ -111.5. LRMS m/z 348 ($M + H$) $^+$.
10 HRMS Calc'd. for $\text{C}_{17}\text{H}_{14}\text{NO}_4\text{FS}$: 348.0706. Observed:
348.0681. Analysis Calc'd. for $\text{C}_{17}\text{H}_{14}\text{NO}_4\text{FS}$: C:,
58.78; H, 4.06; N, 4.03. Observed: C, 58.67; H,
4.02; N, 4.01.

15


EXAMPLE 27

20

4-(4-Fluorophenyl)-2-(2-hydroxyethyl)-5-[4-
(methylsulfonyl)phenyl]oxazole

25

4-(4-Fluorophenyl)-2-(2-hydroxyethyl)-5-[4-
(methylsulfonyl)phenyl]oxazole was prepared in a
manner consistent with that described in Example 20.
The m/z 362 ($M+H$) $^+$ was consistent with the assigned
structure.


EXAMPLE 28

5 **4-(4-Fluorophenyl)-5-[4-(methanesulfonyl)phenyl]-2-phenoxyethyloxazole**

A solution containing 1.69 g (4.87 mmol) of
10 4-(4-fluorophenyl)-2-hydroxymethyl-5-[4-(methanesulfonyl)phenyl]oxazole (Example 26) in 100 mL of methylene chloride was stirred at 25°C as 1.36 mL (9.74 mmol) of triethylamine was added dropwise, followed by the addition of 560 μ L (7.30 mmol) of
15 methanesulfonyl chloride. The reaction was stirred for 20 minutes, after which the organic solution was washed with 1N HCl, dried over sodium sulfate and concentrated in vacuo to give methyl [4-(4-fluorophenyl)-5-[4-(methanesulfonyl)phenyl]oxazol-2-yl]methanesulfonate as a yellow oil which was
20 characterized as the expected mesylate by its NMR spectrum: $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 3.08 (s, 3H), 3.17 (s, 3H), 5.37 (s, 2H), 7.12 (t, 2H, $J=8.8$ Hz), 7.58 (m, 2H), 7.78 (d, 2H, $J=8.8$ Hz) and 7.94 (d, 2H, $J=8.8$
25 Hz). This material was used without further purification. A solution containing 544 mg (1.28 mmol) of methyl [4-(4-fluorophenyl)-5-[4-(methanesulfonyl)phenyl]oxazol-2-yl]methanesulfonate in 20 mL of DMF was stirred at 25°C as 353 mg (2.56 mmol) of
30 of potassium carbonate and 240 mg (2.56 mmol) of

phenol were added. The reaction was stirred for 2 days at 25°C and poured into 100 mL of water. To this mixture was added 100 mL of ethyl acetate and the layers separated. The organic layer was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige solid which was purified by flash chromatography on a silica gel column using 25% ethyl acetate/hexane as the eluent to give 475 mg (88%) of a white solid which was recrystallized from 50% ethyl acetate/isooctane to give a white crystalline solid (mp 168-169°C) whose structure was assigned as 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)-phenyl]-2-phenoxyloxazole on the basis of its spectral characteristics: ¹H-NMR (CDCl₃, 300 MHz) δ 3.07 (s, 3H), 5.23 (s, 2H), 6.98 (m, 5H), 7.33 (t, 2H, J=8.2 Hz), 7.60 (m, 2H), 7.77 (d, 2H, J=8.5 Hz) and 7.92 (d, 2H, J=8.5 Hz). ¹⁹F-NMR (CDCl₃, 280 MHz) δ -111.9. Analysis calc. for C₂₃H₁₈NO₄FS- C: 65.24, H: 4.28, 3.31. Observed- C: 65.10, H: 4.29, N: 3.28.

EXAMPLE 29




4-(4-Fluorophenyl)-2-(pyridyloxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole

4-(4-Fluorophenyl)-2-(pyridyloxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole was prepared in a

manner consistent with Example 28. Melting point:
276-278°C.

EXAMPLE 30




**4-(4-Fluorophenyl)-2-(3-chlorophenoxymethyl)-5-
[4-(methylsulfonyl)phenyl]oxazole**

10

A solution containing 612 mg (1.44 mmol) of methyl [4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]methanesulfonate (as prepared in Example 28) in 20 mL of DMF was
15 stirred at 25°C as 397 mg (2.88 mmol) of potassium carbonate and 0.3 mL (2.88 mmol) of 3-chlorophenol were added. The reaction was stirred for 2 days at 25°C and poured into 100 mL of water. To this mixture was added 100 mL of ethyl acetate and the
20 layers separated. The organic layer was washed with water, dried over sodium sulfate and concentrated in vacuo to give the crude solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent to give 528 mg
25 (80%) of a white solid which was recrystallized from 50% dichloromethane/isooctane to give a white crystalline solid (mp 112-114°C) whose structure was assigned as 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-(3-

chlorophenoxy)methyloxazole on the basis of its spectral characteristics: $^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 3.08 (s, 3H), 5.22 (s, 2H), 7.08 (m, 2H), 7.13 (m, 3H), 7.26 (m, 1H), 7.59 (dd, 2H, $J=8.8$, 5.4 Hz), 7.62 (dd, 2H, $J=8.8$, 5.4 Hz), 7.78 (d, 2H, $J=8.8$ Hz), 7.93 (d, 2H, $J=8.8$ Hz). $^{19}\text{F-NMR}$ (CDCl_3 , 280 MHz) δ -111.8. Analysis Calc'd. for $\text{C}_{23}\text{H}_{17}\text{NO}_4\text{FSCl}$: C, 60.33; H, 3.74; N, 3.06. Observed: C, 60.19; H, 3.80; N, 3.03.

10


EXAMPLE 31

15 4-(4-Fluorophenyl)-2-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole

A solution containing 585 mg (1.37 mmol) of methyl [4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]methanesulfonate (as prepared in Example 28) in 15 mL of DMF was stirred at 25°C as 380 mg (2.74 mmol) of potassium carbonate and 308 mg (2.74 mmol) of 4-fluorophenol are added. The reaction was stirred for 2 days at 25°C and poured into 100 mL of water. To this mixture was added 100 mL of ethyl acetate and the layers separated. The organic layer was washed with water, dried over sodium sulfate and concentrated in vacuo to give the crude solid which was purified by flash

chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent to give 528 mg (80%) of a white solid which was recrystallized from 50% dichloromethane/isooctane to give a white crystalline solid (mp 133-134°C) whose structure was assigned as 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)-phenyl]-2-[(4-fluorophenoxy)methyl]oxazole on the basis of its spectral characteristics: $^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 3.08 (s, 3H), 5.19 (s, 2H), 7.00 (m, 4H), 7.13 (m, 2H), 7.58 (dd, 2H, $J=8.8$, 5.2 Hz), 7.61 (dd, 2H, $J=8.8$, 5.2 Hz), 7.77 (d, 2H, $J=8.7$ Hz), 7.93 (d, 2H, $J=8.7$ Hz). $^{19}\text{F-NMR}$ (CDCl_3 , 280 MHz) δ -111.8, -122.5. Analysis Calc'd. for $\text{C}_{23}\text{H}_{17}\text{NO}_4\text{F}_2\text{S}$: C, 62.58; H, 3.88; N, 3.17. Observed: C, 62.44; H, 4.04; N, 3.11.

EXAMPLE 32




4-(4-Fluorophenyl)-2-(cyclohexylethyl)-5-[4-(methylsulfonyl)phenyl]oxazole

A solution containing 2.02 g (7.24 mmol) of 1-(4-fluorophenyl)-2-hydroxy-2-[4-(methylthiophenyl)ethanone in 100 mL of methylene chloride was stirred at 25°C as 1.76 mL (21.72 mmol) of pyridine was added, followed by the addition of 1.52 g (8.69 mmol) of 2-cyclohexylpropionyl chloride. The reaction was stirred at 25°C for 48 hours, after

which the resulting yellow solution was washed with 1N HCl, dried over sodium sulfate and concentrated in vacuo. The crude solid was purified via flash chromatography on a silica gel column using 10 % ethyl acetate/hexane as the eluent. This provided 2.87 g (96 %) of a white foam, which was characterized as the benzoin ester on the basis of its NMR spectra: ¹H-NMR (CDCl₃, 300 MHz) δ 0.80-0.96 (m, 2H), 1.10-1.25 (m, 4H), 1.45-1.78 (m, 7H), 2.40 (m, 2H), 2.43 (s, 3H), 6.75 (s, 1H), 7.05 (m, 2H), 7.23 (d, 2H, J=8 Hz), 7.35 (d, 2H, J=8 Hz) and 7.95 (m, 2H). ¹⁹F-NMR (CDCl₃, 280 MHz) δ -104.4.

A solution containing 2.87 g (6.92 mmol) of the benzoin ester and 5.3 g (69 mmol) of ammonium acetate in 100 mL of acetic acid was heated to 80°C for 2 hours. The reaction was cooled to 25°C and poured into water. The product was extracted into ethyl acetate and the combined organic extracts washed with an aqueous solution of sodium bicarbonate. The solution was dried over sodium sulfate and concentrated in vacuo to give the crude oxazole. This crude material was purified by flash chromatography on a silica gel column using 25% ethyl acetate/hexane as the eluent to give 1.87 g (68%) of a clear oil, which was characterized as 2-(2-cyclohexylethyl)-4-(4-fluorophenyl)-5-[4-(methythio)phenyl]oxazole on the basis of its spectral properties: ¹H-NMR (CDCl₃, 400 MHz) δ 0.90-1.02 (m, 2H), 1.10-1.40 (m, 4H), 1.62-1.82 (m, 7H), 2.49 (s, 3H), 2.84 (t, J=8.0 Hz, 2H), 7.03 (d, J=8.7Hz, 1H), 7.06 (d, J=8.7Hz, 1H), 7.22 (d, J=8.6Hz, 2H), 7.45 (d, J=8.6Hz, 2H), 7.58 (d, J=5.4Hz, 1H), 7.61 (d, J=5.4Hz, 1H). The material from this experiment was used directly in the next step without further purification.

A solution of 1.87g (4.73 mmol) of 2-(2-cyclohexylethyl)-4-(4-fluorophenyl)-5-[4-(methythio)phenyl]oxazole in 100 mL of methylene chloride was stirred at -78°C as 3.26 g (9.46 mmol based on 50% purity) of m-chloroperoxybenzoic acid was added all at once. The reaction was stirred at -78°C for 1 hour and TLC (silica, 50% hexane/ethyl acetate) indicated that the reaction mixture consisted of mostly sulfone. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent. Recrystallization from 50% ethyl acetate/isooctane gave 1.76 g (87%) of a low melting semi-solid whose structure was assigned as 2-(2-cyclohexylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole on the basis of its spectral characteristics: ¹H-NMR (CDCl₃, 300 MHz) δ 0.90-1.06 (m, 2H), 1.11-1.40 (m, 7H), 2.87 (apparent t, J=8.1Hz, 2H), 3.07 (s, 3H), 7.10 (t, J=8.7Hz, 2H), 7.59 (m, 2H), 7.74 (d, J=8.7Hz, 2H), 7.90 (d, J=8.7Hz, 2H). ¹⁹F-NMR (CDCl₃, 280 MHz) δ -112.49. LRMS m/z 427 (M)+. HRMS Calc'd. for C₂₄H₂₆NO₃FS: 421.1617. Observed: 421.1611. Analysis Calc'd. for C₂₄H₂₆NO₃FS: C, 67.43; H, 6.13; N, 3.28. Observed: C, 67.27; H, 6.15; N, 3.24.

EXAMPLE 33

5 Ethyl 2-[4-(4-fluorophenyl)-5-[4-(
(methylsulfonyl) phenyl]oxazol-2-yl]-2-benzyl-
acetate

10 Step 1: Preparation of 2-(4-fluorophenyl)-3-
(4-methylthiophenyl)propenoic acid

Acetic anhydride (500 mL), 4-
(methylthio)benzaldehyde (100.2 g, 0.66 mol), 4-
15 fluorophenylacetic acid (101.6 g, 0.66 mol), and
triethylamine (68.1 g, 0.67 mol) were placed in a 3 L
round bottom flask and heated to reflux for 1.75 hours.
The reaction was cooled to 110°C, and water (500 mL)
was added cautiously through an addition funnel. This
20 caused the solution to reflux vigorously and the
temperature to rise to 135°C. A yellow precipitate
formed, and after cooling to room temperature, was
collected by filtration, washed with water, and
recrystallized from ethyl acetate/isooctane to provide
25 the diarylacrylic acid as yellow needles (135.2 g,
71%): mp 172-176°C. ¹H NMR (acetone d₆) 300 MHz 7.84
(s, 1H), 7.03-7.28 (m, 10H), 2.46 (s, 3H). ¹⁹F NMR
(acetone d₆) -116.11 (m). Mass spectrum M⁺ 288.

Step 2: Preparation of 1-(4-fluorophenyl)-2-(4-methylthiophenyl)ethanone

5 The diaryl acrylic acid (226.5 g, 0.78 mol) was placed in a 2 L round bottom flask with anhydrous toluene (800 mL) and triethylamine (81.2 g, 0.80 mol). After cooling to 0°C, diphenylphosphoryl azide (217.4 g, 0.79 mol) was added, the solution was stirred at 0°C
10 for 20 minutes and at room temperature for 2.50 hours. The reaction was poured into water, extracted with ether, dried over magnesium sulfate, and concentrated in vacuo to remove the ether. The remaining toluene solution was heated to reflux and a vigorous evolution
15 of gas occurred. After 1.25 hours, tert-butyl alcohol (80 mL, 0.84 mol) was added to the reaction. After an additional 20 minutes, concentrated hydrochloric acid (41 mL) was added slowly causing the reaction to foam. The reaction was heated at 90°C overnight (14 hours)
20 and a white precipitate formed after cooling. The precipitate was isolated by filtration, washed with cold ether, and air dried to yield the desired intermediate (182.7 g, 89%): mp 134.5-138°C. ¹H NMR (acetone d₆) 300 MHz 8.16 (m, 2H), 7.24 (m, 6H), 4.34
25 (s, 2H), 2.46 (s, 3H). ¹⁹F NMR (acetone d₆) -107.88 (m).

Step 3: Preparation of 1-(4-fluorophenyl)-2-(4-methylthiophenyl)-2-hydroxy-ethanone

30

A 1 L three necked round bottomed flask equipped with reflux condenser, magnetic stir bar, thermometer adapter, and constant pressure addition funnel was charged with the intermediate from Step 2,
35 (55.5 g, 0.21 mol), acetic acid (250 mL) and 33% HBr in acetic acid (120 mL). The solution was stirred and treated with bromine (11.1 mL, 0.21 mol) from the

addition funnel at such a rate that the bromine color was discharged rapidly, ca. 15 minutes. After an additional 10 minutes at room temperature, the solution was filtered through a Buchner funnel and the filtrate concentrated in vacuo to give an orange solid. The crude bromoketone was dissolved in dichloromethane and washed with 1N NaHSO₃, dried over anhydrous MgSO₄, filtered and concentrated in vacuo to give 68.8 g of 1-(4-fluorophenyl)-2-(4-methylthiophenyl)-2-bromoethanone as a yellow solid which was used directly without further purification. The crude bromoketone was dissolved in 300 mL acetone and 150 mL of water and heated to reflux for 2.5 hours. The solution was concentrated in vacuo and the residue taken up in dichloromethane, washed with saturated aqueous sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and reconcentrated in vacuo to give a light yellow solid that was crystallized from a mixture of dichloromethane and isooctane to provide 37.8 g (65%) of pure 1-(4-fluorophenyl)-2-(4-methylthiophenyl)-2-hydroxy-ethanone: mp 90-92 °C.

Step 4: Preparation of ethyl 2-[4-(4-fluorophenyl)-5-[4-methylthio]phenyl]oxazol-2-yl]acetate

25

A solution containing 8.00 g (29 mmol) of 1-(4-fluorophenyl)-2-hydroxy-2-[4-(methylthiophenyl)ethanone in 100 mL of methylene chloride was stirred at 25°C as 7.0 mL (31 mmol) of pyridine was added, followed by the addition of 4.5 mL (35 mmol) of ethyl malonyl chloride. The reaction was stirred at 25°C for 48 hours, after which the resulting yellow solution was washed with 1N HCl, dried over sodium sulfate and concentrated in vacuo. The crude solid was purified via flash chromatography on a silica gel column using 10% ethyl acetate/hexane as the eluent. This provided 7.31 g (64%) of a white foam,

which was used directly without further purification. The product from above (7.31 g, 18.7 mmol) and 7.2 g of ammonium acetate (93.5 mmol, 5 equivalents) in 50 mL of glacial acetic were heated to reflux for 2 hours. The
5 reaction mixture was cooled to 25°C and poured into 100 mL of water. The aqueous solution was extracted with ethyl acetate and the combined organic extracts were washed with water and sodium bicarbonate solution, dried over sodium sulfate and concentrated in vacuo.
10 The crude solid was purified by flash chromatography using a silica gel column and 20% ethyl acetate/hexane as the eluent to give a white solid which was recrystallized from 50% ethyl acetate/isooctane to give 5.55 g (80%) of a white solid whose structure was
15 assigned as ethyl 2-[4-(4-fluorophenyl)-5-[4-methylthio)phenyl]oxazol-2-yl]acetate and was judged suitable for taking onto the next step.

20 Step 5: Preparation of ethyl 2-[4-(4-fluorophenyl)-5-[4-methylsulfonyl)phenyl]oxazol-2-yl]-1-benzyl-acetate

A solution of 755 mg (2.03 mmol) of ethyl 2-[4-(4-fluorophenyl)-5-[4-methylthio)phenyl]oxazol-2-yl]acetate (from Step 4) was dissolved in 20 mL of
25 anhydrous tetrahydrofuran (THF) and cooled to -78°C and treated with a solution of potassium bis(trimethylsilyl)amide (2.44 mL, 1.2 equivalents, 1M in THF via syringe. The solution was maintained at
30 -78°C for 15 minutes and treated with a solution of 290 µL (2.44 mmol) of benzyl bromide. The solution was warmed to room temperature and poured into a saturated aqueous solution of ammonium chloride. The aqueous solution was extracted with ethyl acetate, washed with
35 brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give an oil that was purified by flash chromatography on silica gel eluting

with 10% ethyl acetate/hexane to provide 396 mg of the dialkylated product and 182 mg (19%) of ethyl 2-[4-(4-fluorophenyl)-5-[4-methylthio)phenyl]oxazol-2-yl]-1-benzyl-acetate that was used directly in the next step.

- 5 A solution of 182 mg (0.344 mmol) of ethyl 2-[4-(4-fluorophenyl)-5-[4-methylthio)phenyl]oxazol-2-yl]-1-benzyl-acetate in 5 mL of dichloromethane was cooled to -78°C and treated with 272 mg (2 equivalents) of *m*-chloroperoxybenzoic acid for 2 hours. The reaction was
- 10 poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium
- 15 sulfate and concentrated in vacuo to give a transparent oil which was purified by flash chromatography on a silica gel column using 30% ethyl acetate/hexane as the eluent. The purified material was an oil whose structure was assigned as ethyl 2-[4-(4-fluorophenyl)-
- 20 5-[4-methylsulfonyl)phenyl]oxazol-2-yl]-1-benzyl-acetate on the basis of its spectral characteristics: ¹H-NMR (CDCl₃, 300 MHz) δ 1.20 (t, J= 7.0Hz, 3H), 3.07 (s, 3H), 3.53 (m, 2H), 4.19 (q, J= 7.0Hz, 2H), 4.23 (m, 1H), 7.10 (d, J= 8.7Hz, 2H), 7.25 (m, 5H), 7.57 (m,
- 25 2H), 7.70 (d, J= 8.7Hz, 2H), 7.90 (d, J= 8.7Hz, 2H). ¹⁹F-NMR (CDCl₃, 280 MHz) δ -112.15. LRMS m/z 493 (M)+. HRMS Calc'd. for C₂₇H₂₄NO₅FS: 493.1359. Observed: 493.1371.

30

BIOLOGICAL EVALUATION

Rat Carrageenan Foot Pad Edema Test

- The carrageenan foot edema test was
- 35 performed with materials, reagents and procedures essentially as described by Winter, et al., (Proc. Soc. Exp. Biol. Med., 111, 544 (1962)). Mal

Sprague-Dawley rats were selected in each group so that the average body weight was as close as possible. Rats were fasted with free access to water for over sixteen hours prior to the test. The rats were dosed orally (1 mL) with compounds suspended in vehicle containing 0.5% methylcellulose and 0.025% surfactant, or with vehicle alone. One hour later a subplantar injection of 0.1 mL of 1% solution of carrageenan/sterile 0.9% saline was administered and the volume of the injected foot was measured with a displacement plethysmometer connected to a pressure transducer with a digital indicator. Three hours after the injection of the carrageenan, the volume of the foot was again measured. The average foot swelling in a group of drug-treated animals was compared with that of a group of placebo-treated animals and the percentage inhibition of edema was determined (Otterness and Bliven, Laboratory Models for Testing NSAIDs, in Non-steroidal Anti-Inflammatory Drugs, (J. Lombardino, ed. 1985)). The % inhibition shows the % decrease from control paw volume determined in this procedure and the data for selected compounds in this invention are summarized in Table 1.

25

Rat Carrageenan-induced Analgesia Test

The analgesia test using rat carrageenan was performed with materials, reagents and procedures essentially as described by Hargreaves, et al., (Pain, 32, 77 (1988)). Male Sprague-Dawley rats were treated as previously described for the Carrageenan Foot Pad Edema test. Three hours after the injection of the carrageenan, the rats were placed in a special plexiglass container with a transparent floor having a high intensity lamp as a radiant heat source, positionable under the floor. After an initial twenty minute period, thermal stimulation was begun

100

on either the injected foot or on the contralateral uninjected foot. A photoelectric cell turned off the lamp and timer when light was interrupted by paw withdrawal. The time until the rat withdraws its foot was then measured. The withdrawal latency in seconds was determined for the control and drug-treated groups, and percent inhibition of the hyperalgesic foot withdrawal determined. Results are shown in Table I.

10

TABLE I.

	RAT PAW EDEMA		ANALGESIA	
	% Inhibition		% Inhibition	
	@ 10mg/kg body weight		@20mg/kg body weight	
15	Example			
	1	41*	44	
	3	30	-	
	7	24	-	
	8	12	-	
20	10	18	-	
	11	42	-	
	16	26	-	
	28	2	-	
	30	4	-	
25	31	5	-	

* @ 20mg/kg body weight

30 Evaluation of COX I and COX II activity in vitro

The compounds of this invention exhibited inhibition in vitro of COX II. The COX II inhibition activity of the compounds of this invention illustrated in 35 the Examples was determined by the following methods.

a. Preparation of recombinant COX baculoviruses

A 2.0 kb fragment containing the coding region of either human or murine COX-I or human or murine COX-II was cloned into a BamHI site of the baculovirus transfer vector pVL1393 (Invitrogen) to generate the baculovirus transfer vectors for COX-I and COX-II in a manner similar to the method of D.R. O'Reilly et al (*Baculovirus Expression Vectors: A Laboratory Manual* (1992)). Recombinant baculoviruses were isolated by transfecting 4 µg of baculovirus transfer vector DNA into SF9 insect cells (2x10⁸) along with 200 ng of linearized baculovirus plasmid DNA by the calcium phosphate method. See M.D. Summers and G.E. Smith, *A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures*, Texas Agric. Exp. Station Bull. 1555 (1987). Recombinant viruses were purified by three rounds of plaque purification and high titer (10⁷ - 10⁸ pfu/ml) stocks of virus were prepared. For large scale production, SF9 insect cells were infected in 10 liter fermentors (0.5 x 10⁶/ml) with the recombinant baculovirus stock such that the multiplicity of infection was 0.1. After 72 hours the cells were centrifuged and the cell pellet homogenized in Tris/Sucrose (50 mM: 25%, pH 8.0) containing 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The homogenate was centrifuged at 10,000xG for 30 minutes, and the resultant supernatant was stored at -80°C before being assayed for COX activity.

b. Assay for COX I and COX II activity:

COX activity was assayed as PGE₂ formed/µg protein/time using an ELISA to detect the prostaglandin released. CHAPS-solubilized insect cell membranes containing the appropriate COX enzyme were incubated in a potassium phosphate buffer (50 mM, pH 8.0) containing epinephrine, phenol, and heme with the addition of arachidonic acid (10 µM). Compounds were pre-incubated with the enzyme for 10-20 minutes prior to the addition of

arachidonic acid. Any reaction between the arachidonic acid and the enzyme was stopped after ten minutes at 37°C/room temperature by transferring 40 µl of reaction mix into 160 µl ELISA buffer and 25 µM indomethacin. The PGE₂ formed was measured by standard ELISA technology (Cayman Chemical). Results are shown in Table II.

TABLE II.

10		COX I	COX II
		ID ₅₀ µM	ID ₅₀ µM
	Example		
	1	6.9	.02
	3	>10	.04
15	14	>30	>10
	15	>30	.2
	25	>10	.5
	28	>100	.02
	29	>100	100
20	30	>100	.02
	31	>100	.025
	32	15.9	.01
	33	3.1	.05

25

Also embraced within this invention is a class of pharmaceutical compositions comprising one or more compounds of Formula I in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compounds and composition may,

for example, be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.

5 For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of
10 the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.

15 The amount of therapeutically active compound that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of
20 factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain active
25 ingredient in the range of about 0.1 to 1000 mg, preferably in the range of about 0.5 to 500 mg and most preferably between about 1 and 100 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.1 and about 50 mg/kg body weight and most
30 preferably from about 1 to 20 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day.

 For therapeutic purposes, the compounds of
35 this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds

may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric
5 and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be
10 provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be
15 prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil,
20 peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.


25 While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other
antiinfective agents. For example, the compounds of
30 the invention can be administered in combination with antihistamines or with other such agents known heretofore to be effective in combination with antiinflammatory agents. When administered as a
combination, the therapeutic agents can be formulated
35 as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

The examples herein can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims. Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

What is claimed is:

1. A compound of Formula I



I

5

wherein R is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl, alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, heteroaryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, arylthioalkyl, aminocarbonylalkyl, N-alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl;

10

15

20

25

wherein R¹ is selected from cycloalkyl, cycloalkenyl, aryl and heteroaryl, wherein R¹ is optionally substituted at a substitutable position by alkyl, alkoxy and halo; and

wherein R² is selected from alkyl, haloalkyl and amino;

30

or a pharmaceutically-acceptable salt thereof; provided R is not methyl when R² is amino; and further provided that R¹ is not phenyl when R² is methyl and R is isopropyl or tert-butyl.

5

2. Compound of Claim 1 wherein R is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, 10 lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, 15 imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and 20 lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower 25 alkyl and lower alkoxy, lower aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, carboxy, lower carboxyalkyl, lower arylthioalkyl, 30 lower aminocarbonylalkyl, lower N-alkylaminocarbonylalkyl and lower N,N-dialkylaminocarbonylalkyl;

wherein R¹ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl and 35 heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-

dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; and

5 wherein R² is selected from lower alkyl, lower haloalkyl and amino;

 or a pharmaceutically-acceptable salt or prodrug thereof.

10 3. Compound of Claim 2 wherein R is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, 15 trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, hydroxyethenyl, 20 ethynyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butyne, 3-butyne, hydroxyethynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, 25 cycloheptylmethyl, phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyl, 30 thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, 35 benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo,

carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position on the phenyl radical with

5 fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo,

10 carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, carboxy, methyl,

15 ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl,

20 ethoxycarbonylethyl, carboxy, acetyl, propanoic, butanoic, pentanoic, hexanoic, phenylthiomethyl, aminocarbonylmethyl, N-methylaminocarbonylmethyl and N,N-dimethylaminocarbonylmethyl;

wherein R¹ is selected from cyclobutyl,

25 cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, cyclopentenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-

30 dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro,

35 chloro, bromo and iodo; and

110

wherein R² is selected from methyl, ethyl, trifluoromethyl, difluoromethyl, fluoromethyl and amino;

or a pharmaceutically-acceptable salt or
5 prodrug thereof.

4. Compound of Claim 3 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

10

4-[2-benzyl-5-(phenyl)oxazol-4-yl]benzenesulfonamide;

4-[2-benzyl-5-(4-fluorophenyl)oxazol-4-yl]benzenesulfonamide;

15

4-[2-benzyl-5-(3,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;

4-[2-benzyl-5-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;

4-[2-benzyl-5-(3,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;

20

4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;

4-[2-benzyl-5-(3,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;

25

4-[2-benzyl-5-(4-methylphenyl)oxazol-4-yl]benzenesulfonamide;

4-[2-benzyl-5-(3,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;

4-[2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;

30

4-[2-benzyl-5-(4-chloro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;

4-[2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;

35

4-[2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;

4-[2-benzyl-5-(3,5-dichloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(3-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(3-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-thienyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(5-chloro-2-thienyl)oxazol-4-yl]benzenesulfonamide;
10 4-[2-benzyl-5-(cyclohexyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(1-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
15 2-benzyl-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-difluorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chlorophenyl)oxazole;
20 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dichlorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dimethoxyphenyl)oxazole;
25 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dimethylphenyl)oxazole;
30 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-4-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-3-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-4-methoxyphenyl)oxazole;
35 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-3-methoxyphenyl)oxazole;

- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,5-dichloro-4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-4-methylphenyl)oxazole;
5 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-fluoro-3-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-
10 thienyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(5-chloro-2-thienyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(cyclohexyl)oxazole-;
15 2-benzyl-4-(4-methylsulfonylphenyl)-5-(1-cyclohexenyl)oxazole;
2-(ethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(trifluoromethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
20 2-(difluoromethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(hydroxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(carboxy)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
25 2-(methoxycarbonyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(ethoxycarbonyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
30 2-(propyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(benzyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(phenoxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((4-chlorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
35 2-((4-fluorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;

- 2-((4-carboxyphenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(2-phenethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
5 2-(3-phenpropyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(carboxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(ethoxycarbonylmethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
10 2-(methoxycarbonylmethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(2-quinolyloxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
15 4-[2-(ethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
20 4-[2-(hydroxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(carboxy)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
25 4-[2-(ethoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(propyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(benzyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(phenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
30 4-[2-((4-chlorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
35 4-[2-((4-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;

- 4-[2-(2-phenethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
5 4-[2-(carboxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
10 4-[2-(2-quinolyloxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(3,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(3,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(3-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chloro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(3,5-dichloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(3-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
- 5 4-[2-benzyl-4-(4-fluoro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(3-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(2-thienyl)oxazol-5-yl]benzenesulfonamide;
- 10 4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5-yl]benzenesulfonamide;
- 4-[2-benzyl-4-(cyclohexyl)oxazol-5-yl]benzenesulfonamide;
- 15 4-[2-benzyl-4-(1-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-difluorophenyl)oxazole;
- 20 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dichlorophenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-methoxyphenyl)oxazole;
- 25 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dimethoxyphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-methylphenyl)oxazole;
- 30 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dimethylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-4-methylphenyl)oxazole;
- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-3-methylphenyl)oxazole;
- 35 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-4-methoxyphenyl)oxazole;

- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-3-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,5-dichloro-4-methoxyphenyl)oxazole;
5 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-4-methylphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-fluoro-3-methylphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-4-methoxyphenyl)oxazole;
10 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-thienyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(5-chloro-2-thienyl)oxazole;
15 2-benzyl-5-(4-methylsulfonylphenyl)-4-(cyclohexyl)oxazole-;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-cyclohexenyl)oxazole;
2-(ethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
20 2-(trifluoromethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(difluoromethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(hydroxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
25 2-(carboxy)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(methoxycarbonyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
30 2-(ethoxycarbonyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(propyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(benzyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(phenoxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
35 2-((4-chlorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;

- 2-((4-fluorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-((4-carboxyphenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
5 2-(2-phenethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(3-phenpropyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(carboxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
10 2-(ethoxycarbonylmethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(methoxycarbonylmethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
15 2-(2-quinolyloxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
4-[2-(ethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
20 4-[2-(difluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(hydroxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(carboxy)-4-phenyloxazol-5-yl]benzenesulfonamide;
25 4-[2-(methoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(propyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
30 4-[2-(benzyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(phenoxyethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
35 4-[2-((4-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;

- 4-[2-((4-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-phenethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
5 4-[2-(3-phenpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(carboxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
10 4-[2-(methoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-quinolyloxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
15 5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole;
3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid;
methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanate;
20 4-(4-fluorophenyl)-2-(2-phenyl)ethyl-5-(4-(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonylphenyl)oxazole];
25 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
2-benzyl-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-(3-phenyl)propyloxazole;
30 4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-propyloxazole;
2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
35 4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyl-5-[4-methylsulfonylphenyl]oxazole

- 4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyl-5-[4-methylsulfonylphenyl]oxazole;
2-diphenylmethyl-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
5 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetic acid;
ethyl 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanoic acid;
10 methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanoic acid;
15 methyl 4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanamide;
ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonylphenyl]oxazol-2-yl]-2-benzyl-acetate;
20 4-(4-fluorophenyl)-2-(cyclohexylethyl)-5-[4-(methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)-5-[4-(methylsulfonylphenyl]oxazole;
25 4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)-5-[4-(methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-2-(pyridyloxymethyl)-5-[4-(methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonylphenyl)-2-phenoxymethyloxazole;
30 4-(4-fluorophenyl)-2-(2-hydroxyethyl)-5-[4-(methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-2-(hydroxymethyl)-5-[4-(methylsulfonylphenyl]oxazole;
35 4-(cyclohexyl)-2-phenyl-5-[4-(methylsulfonylphenyl]oxazole;

- 4-(4-fluorophenyl)-2-benzyloxymethyl-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-cyclohexyl-5-[4-(methylsulfonyl)phenyl]oxazole; and
5 5-(4-fluorophenyl)-2-phenyl-4-[4-(methylsulfonyl)phenyl]oxazole.

5. Compound of Claim 1 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R¹ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R² is methyl; or a pharmaceutically-acceptable salt thereof; provided R¹ is not phenyl when R is isopropyl or tert-butyl.

30 6. Compound of Claim 5 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower

aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and

wherein R¹ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.

7. Compound of Claim 6 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and

phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R¹ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.

8. Compound of Claim 7 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

- 5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole;
[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazol-2-yl]propanoic acid;
5 methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazol-2-yl]propanate;
4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
10 4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
2-benzyl-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
15 4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-(3-phenyl)propyloxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-propyloxazole;
20 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyl-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyl-5-[4-(methylsulfonyl)phenyl]oxazole;
25 2-diphenylmethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetic acid;
30 ethyl 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanoic acid;
methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanate;
35 4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanoic acid;

- methyl 4-[4-(4-fluorophenyl)-5-[4-methylsulfonyl
 phenyl]oxazol-2-yl]butanate;
 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-
 2-yl]propanamide;
 5 ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)
 phenyl]oxazol-2-yl]-2-benzyl acetate;
 4-(4-fluorophenyl)-2-(cyclohexylethyl)-5-[4-
 (methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)-5-[4-
 10 (methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)-5-[4-
 (methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-2-(pyridyloxymethyl)-5-[4-
 (methylsulfonyl)phenyl]oxazole;
 15 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-
 phenoxymethyl oxazole;
 4-(4-fluorophenyl)-2-(2-hydroxy)ethyl)-5-[4-
 (methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-2-(hydroxymethyl)-5-[4-
 20 (methylsulfonyl)phenyl]oxazole;
 4-(cyclohexyl)-2-phenyl-5-[4-
 (methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-2-benzyloxymethyl-5-[4-
 (methylsulfonyl)phenyl]oxazole;
 25 4-(4-fluorophenyl)-2-cyclohexyl-5-[4-
 (methylsulfonyl)phenyl] oxazole; and
 5-(4-fluorophenyl)-2-phenyl-4-[4-
 (methylsulfonyl)phenyl] oxazole.

- 30 9. Compound of Claim 1 wherein R is
 selected from alkyl, hydroxyalkyl, haloalkyl,
 cycloalkyl, cycloalkylalkyl, aryl optionally
 substituted at a substitutable position by carboxy,
 alkyl, alkoxy and halo, aralkyl optionally
 35 substituted at a substitutable position on the aryl
 radical by carboxy, alkyl, alkoxy and halo,
 aryloxyalkyl optionally substituted at a

- substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl
- 5 optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R^1 is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl
- 10 optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R^2 is amino; or a pharmaceutically-acceptable salt thereof; provided R is not methyl.
- 15 10. Compound of Claim 9 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo,
- 20 carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl
- 25 radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the
- 30 heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R^1 is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl,
- 35 thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-

dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.

5

11. Compound of Claim 10 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 10 chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, 15 cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, 20 ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, 25 bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, 30 isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, 35 methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo,

iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R¹ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.

12. Compound of Claim 11 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

4-[2-benzyl-5-(phenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
10 4-[2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,5-dichloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
15 4-[2-benzyl-5-(3-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-benzyl-5-(2-thienyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(5-chloro-2-thienyl)oxazol-4-yl]benzenesulfonamide;
25 4-[2-benzyl-5-(cyclohexyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(1-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-(ethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
30 4-[2-(trifluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(hydroxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
35 4-[2-(carboxy)-5-phenyloxazol-4-yl]benzenesulfonamide;

- 4-[2-(methoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(ethoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
5 4-[2-(n-propyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(benzyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(phenoxyethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-chlorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
10 4-[2-((4-fluorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
15 4-[2-(2-phenethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(carboxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
20 4-[2-(ethoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
25 4-[2-(2-quinolyloxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(4-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(3,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(3-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chloro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,5-dichloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(3-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-fluoro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(2-thienyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(cyclohexyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(1-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-(ethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
30 4-[2-(trifluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(hydroxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
35 4-[2-(carboxy)-4-phenyloxazol-5-yl]benzenesulfonamide;


- 4-[2-(methoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
5 4-[2-(propyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(benzyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(phenoxyethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
10 4-[2-((4-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
15 4-[2-(2-phenethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(carboxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
20 4-[2-(ethoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(methoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
25 4-[2-(2-quinolyloxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[5-(4-fluorophenyl)-2-methyl-oxazol-4-yl]benzenesulfonamide;
3-[5-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)oxazol-2-yl]propanoic acid;
30 methyl 3-[5-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-2-(2-phenylethyl)-oxazol-5-yl]benzenesulfonamide;
35 4-[4-(4-fluorophenyl)-2-methyl-oxazol-5-yl]benzenesulfonamide;

- 4-[4-(4-fluorophenyl)-2-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[4-(4-fluorophenyl)-2-(3-phenylpropyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(n-propyl)oxazol-5-yl]benzenesulfonamide;
4-[2-(tert-butyl)-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyloxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyloxazol-5-yl]benzenesulfonamide;
15 4-[2-diphenylmethyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]acetic acid;
ethyl 2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]acetate;
20 3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanoic acid;
methyl 3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanate;
25 4-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]butanoic acid;
methyl 4-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]butanate;
3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanamide;
30 ethyl 2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]-2-benzyl-acetate;
4-[4-(4-fluorophenyl)-2-(cyclohexylethyl)oxazol-5-yl]benzenesulfonamide;
35 4-[4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)oxazol-5-yl]benzenesulfonamide;

133

- 4-[4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)oxazol-5-yl]benzenesulfonamide;
 4-[4-(4-fluorophenyl)-2-(pyridyloxymethyl)oxazol-5-yl]benzenesulfonamide;
 5 4-[4-(4-fluorophenyl)-2-phenoxymethyloxazol-5-yl]benzenesulfonamide;
 4-[4-(4-fluorophenyl)-2-(2-hydroxyethyl)oxazol-5-yl]benzenesulfonamide;
 4-[4-(4-fluorophenyl)-2-(hydroxymethyl)oxazol-5-yl]benzenesulfonamide;
 10 4-[4-(cyclohexyl)-2-phenyloxazol-5-yl]benzenesulfonamide;
 4-[4-(4-fluorophenyl)-2-benzyloxymethyloxazol-5-yl]benzenesulfonamide;
 15 4-[4-(4-fluorophenyl)-2-cyclohexyloxazol-5-yl]benzenesulfonamide; and
 4-[5-(4-fluorophenyl)-2-phenyloxazol-4-yl]benzenesulfonamide.

- 20 13. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Formula I



25

- wherein R is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl, alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl, 30 aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, heteroaryl optionally substituted at a substitutable

position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a

5 substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl

10 and alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, arylthioalkyl, aminocarbonylalkyl, N-alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl;

wherein R¹ is selected from cycloalkyl, cycloalkenyl, aryl and heteroaryl, wherein R¹ is optionally substituted at a substitutable position by alkyl, alkoxy and halo; and

wherein R² is selected from alkyl, haloalkyl and amino;

20 or a pharmaceutically-acceptable salt thereof.

14. The composition of Claim 13 wherein R is selected from hydrido, lower alkyl, lower

25 hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo,

30 carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl

35 optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally

substituted at a substitutable position with halo,
carboxy, lower alkyl and lower alkoxy, lower
heteroaryloxyalkyl optionally substituted at a
substitutable position with halo, carboxy, lower
5 alkyl and lower alkoxy, lower aralkoxyalkyl
optionally substituted at a substitutable position
with halo, carboxy, lower alkyl and lower alkoxy,
lower alkoxycarbonyl, lower alkoxycarbonylalkyl,
carboxy, lower carboxyalkyl, lower arylthioalkyl,
10 lower aminocarbonylalkyl, lower N-
alkylaminocarbonylalkyl and lower N,N-
dialkylaminocarbonylalkyl;

wherein R¹ is selected from lower
cycloalkyl, lower cycloalkenyl, phenyl, naphthyl and
15 heteroaryl selected from pyridyl, thienyl, thiazolyl,
oxazolyl, imidazolyl, furyl, quinolyl,
benzothiazolyl, 2,3-thianaphthalenyl, 2,3-
dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-
dihydrobenzofuryl, wherein R¹ is optionally
20 substituted at a substitutable position by lower
alkyl, lower alkoxy and halo; and

wherein R² is selected from lower alkyl,
lower haloalkyl and amino;
or a pharmaceutically-acceptable salt or
25 prodrug thereof.

15. The composition of Claim 14 wherein R
is selected from hydrido, methyl, ethyl, n-propyl,
isopropyl, butyl, tert-butyl, isobutyl,
30 hydroxymethyl, fluoromethyl, difluoromethyl,
trifluoromethyl, chloromethyl, dichloromethyl,
trichloromethyl, pentafluoroethyl, heptafluoropropyl,
difluorochloromethyl, dichlorofluoromethyl,
difluoroethyl, difluoropropyl, dichloroethyl,
35 dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1-
butenyl, 2-butenyl, 3-butenyl, hydroxyethenyl,
ethynyl, 1-propynyl, 2-propynyl, 1-butyne, 2-

- butynyl, 3-butynyl, hydroxyethynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,
- 5 cycloheptylmethyl, phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyl,
- 10 thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy,
- 15 benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl
- 20 optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl
- 25 optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,
- 30 butoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, carboxy, acetyl, propanoic,
- 35

butanoic, pentanoic, hexanoic, phenylthiomethyl, aminocarbonylmethyl, N-methylaminocarbonylmethyl and N,N-dimethylaminocarbonylmethyl;

wherein R¹ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, cyclopentenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; and

wherein R² is selected from methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl and amino;

or a pharmaceutically-acceptable salt or prodrug thereof.

16. The composition of Claim 15 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

4-[2-benzyl-5-(phenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(3,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(3,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
10 4-[2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
15 4-[2-benzyl-5-(3,5-dichloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-benzyl-5-(3-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-thienyl)oxazol-4-yl]benzenesulfonamide;
25 4-[2-benzyl-5-(5-chloro-2-thienyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(cyclohexyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(1-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
30 2-benzyl-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-difluorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chlorophenyl)oxazole;
35 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dichlorophenyl)oxazole;

- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dimethoxyphenyl)oxazole;
5 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dimethylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-4-methylphenyl)oxazole;
10 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-3-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-4-methoxyphenyl)oxazole;
15 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-3-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,5-dichloro-4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-4-methylphenyl)oxazole;
20 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-fluoro-3-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-4-methoxyphenyl)oxazole;
25 2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-thienyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(5-chloro-2-thienyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(cyclohexyl)oxazole-;
30 2-benzyl-4-(4-methylsulfonylphenyl)-5-(1-cyclohexenyl)oxazole;
2-(ethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(trifluoromethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
35 2-(difluoromethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;

- 2-(hydroxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(carboxy)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
5 2-(methoxycarbonyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(ethoxycarbonyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(propyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
10 2-(benzyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(phenoxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((4-chlorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
15 2-((4-fluorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((4-carboxyphenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(2-phenethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
20 2-(3-phenpropyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(carboxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
25 2-(ethoxycarbonylmethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(methoxycarbonylmethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(2-quinolyloxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
30 4-[2-(ethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamid ;
35 4-[2-(hydroxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;

- 4-[2-(carboxy)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(ethoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
5 4-[2-(propyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(benzyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(phenoxyethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
10 4-[2-((4-chlorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
15 4-[2-(2-phenethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
20 4-[2-(carboxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
25 4-[2-(2-quinolyloxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(3,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(3,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[2-benzyl-4-(4-chloro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,5-dichloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(4-fluoro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(2-thienyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(cyclohexyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(1-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
2-benzyl-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-difluorophenyl)oxazole;
35 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;

- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dichlorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-methoxyphenyl)oxazole;
5 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dimethoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-methylphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dimethylphenyl)oxazole;
10 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-4-methylphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-3-methylphenyl)oxazole;
15 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-4-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-3-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,5-dichloro-4-methoxyphenyl)oxazole;
20 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-4-methylphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-fluoro-3-methylphenyl)oxazole;
25 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-4-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-thienyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(5-chloro-2-thienyl)oxazole;
30 2-benzyl-5-(4-methylsulfonylphenyl)-4-(cyclohexyl)oxazole-;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-cyclohexenyl)oxazole;
35 2-(ethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(trifluoromethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;

- 2-(difluoromethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(hydroxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 5 2-(carboxy)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(methoxycarbonyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(ethoxycarbonyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 10 2-(propyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(benzyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(phenoxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 15 2-((4-chlorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-((4-fluorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-((4-carboxyphenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 20 2-(2-phenethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(3-phenpropyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 25 2-(carboxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(ethoxycarbonylmethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(methoxycarbonylmethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 30 2-(2-quinolyloxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 4-[2-(ethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(trifluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 35 4-[2-(difluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;

- 4-[2-(hydroxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(carboxy)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
5 4-[2-(ethoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(propyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(benzyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
10 4-[2-(phenoxyethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
15 4-[2-((4-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-phenethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
20 4-[2-(3-phenpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(carboxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
25 4-[2-(methoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-quinolyloxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
30 5-(4-fluorophenyl)-2-methyl-4-[4-(methanesulfonyl)phenyl]oxazole;
3-[5-(4-fluorophenyl)-4-[4-(methanesulfonyl)phenyl]oxazol-2-yl]propanoic acid;
methyl 3-[5-(4-fluorophenyl)-4-[4-(methanesulfonyl)phenyl]oxazol-2-yl]propanate;
35 4-(4-fluorophenyl)-2-(2-phenyl)ethyl-5-(4-(methanesulfonyl)phenyl)oxazole;

- 4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonylphenyl)oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonylphenyl)-2-phenyloxazole;
5 2-benzyl-4-(4-fluorophenyl)-5-(4-(methylsulfonylphenyl)oxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-(3-phenyl)propyloxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-propyloxazole;
10 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyl-5-[4-methylsulfonylphenyl]oxazole
15 4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyl-5-[4-methylsulfonylphenyl]oxazole;
2-diphenylmethyl-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetic acid;
20 ethyl 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanoic acid;
25 methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanoic acid;
methyl 4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanate;
30 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanamide;
ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonylphenyl]oxazol-2-yl]-2-benzyl-acetate;
35 4-(4-fluorophenyl)-2-(cyclohexylethyl)-5-[4-(methylsulfonylphenyl]oxazole;

- 4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
5 4-(4-fluorophenyl)-2-(pyridyloxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenoxymethyloxazole;
4-(4-fluorophenyl)-2-(2-hydroxyethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
10 4-(4-fluorophenyl)-2-(hydroxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(cyclohexyl)-2-phenyl-5-[4-(methylsulfonyl)phenyl]oxazole;
15 4-(4-fluorophenyl)-2-benzyloxymethyl-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-cyclohexyl-5-[4-(methylsulfonyl)phenyl]oxazole; and
5-(4-fluorophenyl)-2-phenyl-4-[4-(methylsulfonyl)phenyl]oxazole.
20

17. The composition of Claim 13 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R¹ is selected from cycloalkyl, cycloalkenyl, heteroaryl and
- 25
30
35

aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R² is methyl; or a pharmaceutically-acceptable salt thereof.

- 5 18. The composition of Claim 17 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable
10 position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable
15 position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a
20 substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxy-carbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and

- wherein R¹ is selected from lower
25 cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is
30 optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.

19. The composition of Claim 18 wherein R
35 is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl,

chloromethyl, dichloromethyl, trichloromethyl,
pentafluoroethyl, heptafluoropropyl,
difluorochloromethyl, dichlorofluoromethyl,
difluoroethyl, difluoropropyl, dichloroethyl,
5 dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, cyclobutylmethyl, cyclopentylmethyl,
cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,
cycloheptylmethyl, aryl selected from phenyl and
naphthyl, optionally substituted at a substitutable
10 position by fluoro, chloro, bromo, iodo, methyl,
ethyl, n-propyl, isopropyl, butyl, tert-butyl,
isobutyl, carboxy, methoxy, ethoxy, propoxy and
butoxy, benzyl, phenethyl, diphenylmethyl and
phenpropyl, optionally substituted at a substitutable
15 position on the phenyl radical by fluoro, chloro,
bromo, iodo, methyl, ethyl, n-propyl, isopropyl,
butyl, tert-butyl, isobutyl, carboxy, methoxy,
ethoxy, propoxy and butoxy, phenoxymethyl optionally
substituted at a substitutable position with fluoro,
20 chloro, bromo, iodo, methyl, ethyl, n-propyl,
isopropyl, butyl, tert-butyl, isobutyl, carboxy,
methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl
optionally substituted at a substitutable position by
fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl,
25 isopropyl, butyl, tert-butyl, isobutyl, carboxy,
methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl
and quinolyloxymethyl, optionally substituted at a
substitutable position by fluoro, chloro, bromo,
iodo, methyl, ethyl, n-propyl, isopropyl, butyl,
30 tert-butyl, isobutyl, carboxy, methoxy, ethoxy,
propoxy and butoxy, methoxycarbonylmethyl,
ethoxycarbonylmethyl, methoxycarbonylethyl,
ethoxycarbonylethyl, acetyl, propanoic, butanoic,
pentanoic, hexanoic and aminocarbonylmethyl; and
35 wherein R¹ is selected from cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-
cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl,

pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is
5 optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a
pharmaceutically-acceptable salt or prodrug thereof.

10

20. The composition of Claim 19 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

15

5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole;
[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazol-2-yl]propanoic acid;
20 methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazol-2-yl]propanate;
4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole;
25 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
2-benzyl-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
30 4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-(3-phenyl)propyloxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-propyloxazole;
2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
35 4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyl-5-[4-methylsulfonylphenyl]oxazole

- 4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyl-5-[4-methylsulfonylphenyl]oxazole;
2-diphenylmethyl-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
5 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetic acid;
ethyl 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanoic acid;
10 methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanoic acid;
15 methyl 4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]butanate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]propanamide;
ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]-2-benzyl acetate;
20 4-(4-fluorophenyl)-2-(cyclohexylethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
25 4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(pyridyloxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenoxymethyl oxazole;
30 4-(4-fluorophenyl)-2-(2-hydroxy)ethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(hydroxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
35 4-(cyclohexyl)-2-phenyl-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-benzyloxymethyl-5-[4-

(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-cyclohexyl-5-[4-
(methylsulfonyl)phenyl] oxazole; and
5-(4-fluorophenyl)-2-phenyl-4-[4-
5 (methylsulfonyl)phenyl] oxazole.

21. The composition of Claim 13 wherein R
is selected from alkyl, hydroxyalkyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl optionally
10 substituted at a substitutable position by carboxy,
alkyl, alkoxy and halo, aralkyl optionally
substituted at a substitutable position on the aryl
radical by carboxy, alkyl, alkoxy and halo,
aryloxyalkyl optionally substituted at a
15 substitutable position on the aryl radical with halo,
carboxy, alkyl and alkoxy, aralkoxyalkyl optionally
substituted at a substitutable position by alkyl,
carboxy, alkoxy and halo, heteroaryloxyalkyl
optionally substituted at a substitutable position on
20 the heteroaryl radical with halo, carboxy, alkyl and
alkoxy, alkoxy carbonylalkyl, carboxyalkyl and
aminocarbonylalkyl; wherein R¹ is selected from
cycloalkyl, cycloalkenyl, heteroaryl and aryl
optionally substituted at a substitutable position by
25 alkyl, alkoxy and halo; and wherein R² is amino; or a
pharmaceutically-acceptable salt thereof.

22. The composition of Claim 21 wherein R
is selected from lower alkyl, lower hydroxyalkyl,
30 lower haloalkyl, lower cycloalkyl, lower
cycloalkylalkyl, aryl selected from phenyl and
naphthyl, optionally substituted at a substitutable
position by halo, carboxy, lower alkyl and lower
alkoxy, lower aralkyl optionally substituted at a
35 substitutable position on the aryl radical by halo,
carboxy, lower alkyl and lower alkoxy, lower
aryloxyalkyl optionally substituted at a

substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower
5 heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R¹ is selected from
10 lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is
15 optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.

23. The composition of Claim 22 wherein R
20 is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl,
25 difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,
30 cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and
35 butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro,

bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R¹ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.

24. The composition of Claim 23 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

- 4-[2-benzyl-5-(phenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
10 4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
15 4-[2-benzyl-5-(3,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-benzyl-5-(4-chloro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
25 4-[2-benzyl-5-(3,5-dichloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
30 4-[2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-thienyl)oxazol-4-yl]benzenesulfonamide;
35 4-[2-benzyl-5-(5-chloro-2-thienyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(cyclohexyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(1-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-(ethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
10 4-[2-(hydroxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(carboxy)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
15 4-[2-(ethoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(n-propyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(benzyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(phenoxyethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
20 4-[2-((4-chlorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
25 4-[2-((4-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(2-phenethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
30 4-[2-(carboxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
35 4-[2-(methoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;

- 4-[2-(2-quinolyloxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(4-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[2-benzyl-4-(4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(3,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(4-chloro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(3,5-dichloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(4-fluoro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2-thienyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(cyclohexyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(1-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-(ethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
10 4-[2-(hydroxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(carboxy)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
15 4-[2-(ethoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(propyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(benzyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(phoxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
20 4-[2-((4-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
25 4-[2-((4-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-phenethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
30 4-[2-(carboxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
35 4-[2-(methoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;


- 4-[2-(2-quinolyloxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[5-(4-fluorophenyl)-2-methyl-oxazol-4-yl]benzenesulfonamide;
5 3-[5-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)oxazol-2-yl]propanoic acid;
methyl 3-[5-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-2-(2-phenylethyl)-oxazol-5-yl]benzenesulfonamide;
10 4-[4-(4-fluorophenyl)-2-methyl-oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-phenyloxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(3-phenylpropyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(n-propyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-(tert-butyl)-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyloxazol-5-yl]benzenesulfonamide;
25 4-[4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyloxazol-5-yl]benzenesulfonamide;
4-[2-diphenylmethyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]acetic acid;
30 ethyl 2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]acetate;
3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanoic acid;
35 methyl 3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-

2-yl]butanoic acid;
methyl 4-[4-(4-fluorophenyl)-5-[4-aminosulfonyl
phenyl]oxazol-2-yl]butanate;
3-[4-(4-fluorophenyl)-5-[4-aminosulfonyl
5 phenyl]oxazol-2-yl]propanamide;
ethyl 2-[4-(4-fluorophenyl)-5-[4-aminosulfonyl
phenyl]oxazol-2-yl]-2-benzyl-acetate;
4-[4-(4-fluorophenyl)-2-(cyclohexylethyl)oxazol-5-
yl]benzenesulfonamide;
10 4-[4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)oxazol-
5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)oxazol-
5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(pyridyloxymethyl)oxazol-5-
15 yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-phenoxyethyloxazol-5-
yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(2-hydroxyethyl)oxazol-5-
yl]benzenesulfonamide;
20 4-[4-(4-fluorophenyl)-2-(hydroxymethyl)oxazol-5-
yl]benzenesulfonamide;
4-[4-(cyclohexyl)-2-phenyloxazol-5-
yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-benzyloxymethyloxazol-5-
25 yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-cyclohexyloxazol-5-
yl]benzenesulfonamide; and
4-[5-(4-fluorophenyl)-2-phenyloxazol-4-
yl]benzenesulfonamide.

30

25. A method of treating inflammation or an
inflammation-associated disorder in a subject, said
method comprising administering to the subject having
such inflammation or inflammation-associated
35 disorder, a therapeutically-effective amount of a
compound of Formula I

161

**I**

wherein R is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl, alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, heteroaryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, arylthioalkyl, aminocarbonylalkyl, N-alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl;

wherein R¹ is selected from cycloalkyl, cycloalkenyl, aryl and heteroaryl, wherein R¹ is optionally substituted at a substitutable position by alkyl, alkoxy and halo; and

wherein R² is selected from alkyl, haloalkyl and amino;

or a pharmaceutically-acceptable salt thereof.

26. The method of Claim 25 wherein R is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, 5 lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, 10 imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and 15 lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower aralkoxyalkyl 20 optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, carboxy, lower carboxyalkyl, lower arylthioalkyl, 25 lower aminocarbonylalkyl, lower N-alkylaminocarbonylalkyl and lower N,N-dialkylaminocarbonylalkyl;

wherein R¹ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl and 30 heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally 35 substituted at a substitutable position by lower alkyl, lower alkoxy and halo; and

wherein R² is selected from lower alkyl,
lower haloalkyl and amino;

or a pharmaceutically-acceptable salt or
prodrug thereof.

5

27. The method of Claim 26 wherein R is
selected from hydrido, methyl, ethyl, n-propyl,
isopropyl, butyl, tert-butyl, isobutyl,
hydroxymethyl, fluoromethyl, difluoromethyl,
10 trifluoromethyl, chloromethyl, dichloromethyl,
trichloromethyl, pentafluoroethyl, heptafluoropropyl,
difluorochloromethyl, dichlorofluoromethyl,
difluoroethyl, difluoropropyl, dichloroethyl,
dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1-
15 butenyl, 2-butenyl, 3-butenyl, hydroxyethenyl,
ethynyl, 1-propynyl, 2-propynyl, 1-butyne, 2-
butynyl, 3-butyne, hydroxyethynyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl,
cyclobutylmethyl, cyclopentylmethyl,
20 cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,
cycloheptylmethyl, phenyl and naphthyl, optionally
substituted at a substitutable position by fluoro,
chloro, bromo, iodo, carboxy, methyl, ethyl, n-
propyl, isopropyl, butyl, tert-butyl, isobutyl,
25 methoxy, ethoxy, propoxy and butoxy, pyridyl,
thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and
quinolyl, optionally substituted at a substitutable
position by fluoro, chloro, bromo, iodo, carboxy,
methyl, ethyl, n-propyl, isopropyl, butyl, tert-
30 butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy,
benzyl, phenethyl, diphenylmethyl and phenpropyl,
optionally substituted at a substitutable position on
the phenyl radical by fluoro, chloro, bromo, iodo,
carboxy, methyl, ethyl, n-propyl, isopropyl, butyl,
35 tert-butyl, isobutyl, methoxy, ethoxy, propoxy and
butoxy, phenoxymethyl optionally substituted at a
substitutable position on the phenyl radical with

- fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position on
- 5 the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl optionally substituted at a substitutable position
- 10 with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, carboxy, acetyl, propanoic, butanoic, pentanoic, hexanoic, phenylthiomethyl, aminocarbonylmethyl, N-methylaminocarbonylmethyl and N,N-dimethylaminocarbonylmethyl;
- 15 wherein R¹ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, cyclopentenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-
- 25 dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; and
- 30 wherein R² is selected from methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl and amino;
- 35 or a pharmaceutically-acceptable salt or prodrug thereof.

28. The method of Claim 27 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

- 5 4-[2-benzyl-5-(phenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
- 10 4-[2-benzyl-5-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 15 4-[2-benzyl-5-(3,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 20 4-[2-benzyl-5-(3,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-chloro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 25 4-[2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 30 4-[2-benzyl-5-(3,5-dichloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 35 4-[2-benzyl-5-(3-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(2-thienyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(5-chloro-2-thienyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(cyclohexyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(1-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
2-benzyl-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
10 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-difluorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chlorophenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dichlorophenyl)oxazole;
15 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dimethoxyphenyl)oxazole;
20 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,4-dimethylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-4-methylphenyl)oxazole;
25 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-3-methylphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-chloro-4-methoxyphenyl)oxazole;
30 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-chloro-3-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3,5-dichloro-4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-4-methylphenyl)oxazole;
35 2-benzyl-4-(4-methylsulfonylphenyl)-5-(4-fluoro-3-methylphenyl)oxazole;

- 2-benzyl-4-(4-methylsulfonylphenyl)-5-(3-fluoro-4-methoxyphenyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(2-thienyl)oxazole;
5 2-benzyl-4-(4-methylsulfonylphenyl)-5-(5-chloro-2-thienyl)oxazole;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(cyclohexyl)oxazole-;
2-benzyl-4-(4-methylsulfonylphenyl)-5-(1-cyclohexenyl)oxazole;
10 2-(ethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(trifluoromethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(difluoromethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
15 2-(hydroxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(carboxy)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
20 2-(methoxycarbonyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(ethoxycarbonyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(propyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
25 2-(benzyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(phenoxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((4-chlorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
30 2-((4-fluorophenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-((4-carboxyphenoxy)methyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(2-phenethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
35 2-(3-phenpropyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;

- 2-(carboxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(ethoxycarbonylmethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
5 2-(methoxycarbonylmethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
2-(2-quinolyloxymethyl)-4-(4-methylsulfonylphenyl)-5-phenyloxazole;
4-[2-(ethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
10 4-[2-(trifluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(hydroxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
15 4-[2-(carboxy)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(ethoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
20 4-[2-(propyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(benzyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(phenoxyethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
25 4-[2-((4-chlorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
30 4-[2-(2-phenethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
35 4-[2-(carboxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;

- 4-[2-(ethoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
5 4-[2-(2-quinolyloxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[2-benzyl-4-(3,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(4-chloro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,5-dichloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(4-fluoro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(3-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2-thienyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(cyclohexyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(1-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
10 2-benzyl-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-difluorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
15 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dichlorophenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-methoxyphenyl)oxazole;
20 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dimethoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-methylphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,4-dimethylphenyl)oxazole;
25 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-4-methylphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-3-methylphenyl)oxazole;
30 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-chloro-4-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-chloro-3-methoxyphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3,5-dichloro-4-methoxyphenyl)oxazole;
35 2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-4-methylphenyl)oxazole;

- 2-benzyl-5-(4-methylsulfonylphenyl)-4-(4-fluoro-3-methylphenyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(3-fluoro-4-methoxyphenyl)oxazole;
5 2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-thienyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(5-chloro-2-thienyl)oxazole;
2-benzyl-5-(4-methylsulfonylphenyl)-4-
10 (cyclohexyl)oxazole-;
2-benzyl-5-(4-methylsulfonylphenyl)-4-(2-cyclohexenyl)oxazole;
2-(ethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(trifluoromethyl)-5-(4-methylsulfonylphenyl)-4-
15 phenyloxazole;
2-(difluoromethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(hydroxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
20 2-(carboxy)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(methoxycarbonyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(ethoxycarbonyl)-5-(4-methylsulfonylphenyl)-4-
25 phenyloxazole;
2-(propyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(benzyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-(phenoxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
30 2-((4-chlorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-((4-fluorophenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
2-((4-carboxyphenoxy)methyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
35 2-(2-phenethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;

- 2-(3-phenpropyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(carboxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 5 2-(ethoxycarbonylmethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(methoxycarbonylmethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 2-(2-quinolyloxymethyl)-5-(4-methylsulfonylphenyl)-4-phenyloxazole;
- 10 4-[2-(ethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(trifluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(difluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 15 4-[2-(hydroxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(carboxy)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(methoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 20 4-[2-(ethoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(propyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(benzyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 25 4-[2-(phenoxyethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-((4-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-((4-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 30 4-[2-((4-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 4-[2-(2-phenethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
- 35 4-[2-(3-phenpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;

- 4-[2-(carboxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
5 4-[2-(methoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-quinolyloxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole;
10 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid;
methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]oxazol-2-yl]propanate;
15 4-(4-fluorophenyl)-2-(2-phenyl)ethyl-5-(4-(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonylphenyl)oxazole];
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
20 2-benzyl-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-(3-phenyl)propyloxazole;
25 4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-propyloxazole;
2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyl-5-[4-methylsulfonylphenyl]oxazole
30 4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyl-5-[4-methylsulfonylphenyl]oxazole;
2-diphenylmethyl-4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazole;
35 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-2-yl]acetic acid;

- ethyl 2-[4-(4-fluorophenyl)-5-[4-methylsulfonyl]phenyl]oxazol-2-yl]acetate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonyl]phenyl]oxazol-2-yl]propanoic acid;
5 methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonyl]phenyl]oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-5-[4-methylsulfonyl]phenyl]oxazol-2-yl]butanoic acid;
methyl 4-[4-(4-fluorophenyl)-5-[4-methylsulfonyl]phenyl]oxazol-2-yl]butanate;
10 3-[4-(4-fluorophenyl)-5-[4-methylsulfonyl]phenyl]oxazol-2-yl]propanamide;
ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]-2-benzyl-acetate;
15 4-(4-fluorophenyl)-2-(cyclohexylethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
20 4-(4-fluorophenyl)-2-(pyridyloxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenoxymethyloxazole;
25 4-(4-fluorophenyl)-2-(2-hydroxyethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-(hydroxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(cyclohexyl)-2-phenyl-5-[4-(methylsulfonyl)phenyl]oxazole;
30 4-(4-fluorophenyl)-2-benzyloxymethyl-5-[4-(methylsulfonyl)phenyl]oxazole;
4-(4-fluorophenyl)-2-cyclohexyl-5-[4-(methylsulfonyl)phenyl]oxazole; and
35 5-(4-fluorophenyl)-2-phenyl-4-[4-(methylsulfonyl)phenyl]oxazole.

29. The method of Claim 25 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R¹ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R² is methyl; or a pharmaceutically-acceptable salt thereof.

20

30. The method of Claim 29 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and

35

lower alkoxy, lower alkoxycarbonylalkyl, lower
carboxyalkyl and lower aminocarbonylalkyl; and
wherein R¹ is selected from lower
cycloalkyl, lower cycloalkenyl, phenyl, naphthyl,
5 pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl,
furyl, quinolyl, benzothiazolyl, 2,3-
thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-
benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is
optionally substituted at a substitutable position by
10 lower alkyl, lower alkoxy and halo; or a
pharmaceutically-acceptable salt or prodrug thereof.

31. The method of Claim 30 wherein R is
selected from methyl, ethyl, n-propyl, isopropyl,
15 butyl, tert-butyl, isobutyl, hydroxymethyl,
fluoromethyl, difluoromethyl, trifluoromethyl,
chloromethyl, dichloromethyl, trichloromethyl,
pentafluoroethyl, heptafluoropropyl,
difluorochloromethyl, dichlorofluoromethyl,
20 difluoroethyl, difluoropropyl, dichloroethyl,
dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, cyclobutylmethyl, cyclopentylmethyl,
cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,
cycloheptylmethyl, aryl selected from phenyl and
25 naphthyl, optionally substituted at a substitutable
position by fluoro, chloro, bromo, iodo, methyl,
ethyl, n-propyl, isopropyl, butyl, tert-butyl,
isobutyl, carboxy, methoxy, ethoxy, propoxy and
butoxy, benzyl, phenethyl, diphenylmethyl and
30 phenpropyl, optionally substituted at a substitutable
position on the phenyl radical by fluoro, chloro,
bromo, iodo, methyl, ethyl, n-propyl, isopropyl,
butyl, tert-butyl, isobutyl, carboxy, methoxy,
ethoxy, propoxy and butoxy, phenoxymethyl optionally
35 substituted at a substitutable position with fluoro,
chloro, bromo, iodo, methyl, ethyl, n-propyl,
isopropyl, butyl, tert-butyl, isobutyl, carboxy,

- methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy,
- 5 methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy,
- 10 propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R¹ is selected from cyclobutyl, cyclopentyl,
- 15 cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a
- 25 pharmaceutically-acceptable salt or prodrug thereof.

32. The method of Claim 31 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

30

- 5-(4-fluorophenyl)-2-methyl-4-[4-(methylsulfonyl)phenyl]oxazole;
- [5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazol-2-yl]propanoic acid;
- 35 methyl 3-[5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-2-oxazol-2-yl]propanate;
- 4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-

- (methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-2-methyl-5-[4-
methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-
5 phenyloxazole;
2-benzyl-4-(4-fluorophenyl)-5-(4-
(methylsulfonyl)phenyl)oxazole;
4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-(3-
phenyl)propyloxazole;
10 4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]-2-
propyloxazole;
2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-
methylsulfonylphenyl]oxazole;
4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyl-5-[4-
15 methylsulfonylphenyl]oxazole
4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyl-5-[4-
methylsulfonylphenyl]oxazole;
2-diphenylmethyl-4-(4-fluorophenyl)-5-[4-
methylsulfonylphenyl]oxazole;
20 2-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-
2-yl]acetic acid;
ethyl 2-[4-(4-fluorophenyl)-5-[4-methylsulfonyl
phenyl]oxazol-2-yl]acetate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-
25 2-yl]propanoic acid;
methyl 3-[4-(4-fluorophenyl)-5-[4-methylsulfonyl
phenyl]oxazol-2-yl]propanate;
4-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-
2-yl]butanoic acid;
30 methyl 4-[4-(4-fluorophenyl)-5-[4-methylsulfonyl
phenyl]oxazol-2-yl]butanate;
3-[4-(4-fluorophenyl)-5-[4-methylsulfonylphenyl]oxazol-
2-yl]propanamide;
ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)
35 phenyl]oxazol-2-yl]-2-benzyl acetate;
4-(4-fluorophenyl)-2-(cyclohexylethyl)-5-[4-
(methylsulfonyl)phenyl]oxazole;

- 4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
 5 4-(4-fluorophenyl)-2-(pyridyloxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenoxymethyl oxazole;
 4-(4-fluorophenyl)-2-(2-hydroxy)ethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
 10 4-(4-fluorophenyl)-2-(hydroxymethyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
 4-(cyclohexyl)-2-phenyl-5-[4-(methylsulfonyl)phenyl]oxazole;
 15 4-(4-fluorophenyl)-2-benzyloxymethyl-5-[4-(methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-2-cyclohexyl-5-[4-(methylsulfonyl)phenyl] oxazole; and
 5-(4-fluorophenyl)-2-phenyl-4-[4-(methylsulfonyl)phenyl] oxazole.
 20

33. The method of Claim 25 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R¹ is selected from
- 25
- 30
- 35

cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R² is amino; or a pharmaceutically-acceptable salt thereof; provided R
5 is not methyl.

34. The method of Claim 33 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl,
10 aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and
15 lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl
20 and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxy carbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and
25 wherein R¹ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally
30 substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.

35 35. The method of Claim 34 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl,

fluoromethyl, difluoromethyl, trifluoromethyl,
chloromethyl, dichloromethyl, trichloromethyl,
pentafluoroethyl, heptafluoropropyl,
difluorochloromethyl, dichlorofluoromethyl,
5 difluoroethyl, difluoropropyl, dichloroethyl,
dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, cyclobutylmethyl, cyclopentylmethyl,
cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl,
cycloheptylmethyl, aryl selected from phenyl and
10 naphthyl, optionally substituted at a substitutable
position by fluoro, chloro, bromo, iodo, methyl,
ethyl, n-propyl, isopropyl, butyl, tert-butyl,
isobutyl, carboxy, methoxy, ethoxy, propoxy and
butoxy, benzyl, phenethyl, diphenylmethyl and
15 phenpropyl, optionally substituted at a substitutable
position on the phenyl radical by fluoro, chloro,
bromo, iodo, methyl, ethyl, n-propyl, isopropyl,
butyl, tert-butyl, isobutyl, carboxy, methoxy,
ethoxy, propoxy and butoxy, phenoxymethyl optionally
20 substituted at a substitutable position with fluoro,
chloro, bromo, iodo, methyl, ethyl, n-propyl,
isopropyl, butyl, tert-butyl, isobutyl, carboxy,
methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl
optionally substituted at a substitutable position by
25 fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl,
isopropyl, butyl, tert-butyl, isobutyl, carboxy,
methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl
and quinolyloxymethyl, optionally substituted at a
substitutable position by fluoro, chloro, bromo,
30 iodo, methyl, ethyl, n-propyl, isopropyl, butyl,
tert-butyl, isobutyl, carboxy, methoxy, ethoxy,
propoxy and butoxy, methoxycarbonylmethyl,
ethoxycarbonylmethyl, methoxycarbonylethyl,
ethoxycarbonylethyl, acetyl, propanoic, butanoic,
35 pentanoic, hexanoic and aminocarbonylmethyl; and
wherein R¹ is selected from cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-

cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3-dihydrobenzofuryl, wherein R¹ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a
pharmaceutically-acceptable salt or prodrug thereof.

36. Compound of Claim 35 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of

- 4-[2-benzyl-5-(phenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-fluorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3,4-difluorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-chlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3,4-dichlorophenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3,4-dimethoxyphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3,4-dimethylphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
- 4-[2-benzyl-5-(4-chloro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;

- 4-[2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
5 4-[2-benzyl-5-(3,5-dichloro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(3-fluoro-4-methylphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl]benzenesulfonamide;
10 4-[2-benzyl-5-(3-fluoro-4-methoxyphenyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(2-thienyl)oxazol-4-yl]benzenesulfonamide;
15 4-[2-benzyl-5-(5-chloro-2-thienyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(cyclohexyl)oxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-5-(1-cyclohexenyl)oxazol-4-yl]benzenesulfonamide;
20 4-[2-(ethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
25 4-[2-(hydroxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(carboxy)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
30 4-[2-(ethoxycarbonyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(n-propyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(benzyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
35 4-[2-(phenoxyethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;

- 4-[2-((4-chlorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
5 4-[2-((4-carboxyphenoxy)methyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(2-phenethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
10 4-[2-(carboxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
15 4-[2-(methoxycarbonylmethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-(2-quinolyloxymethyl)-5-phenyloxazol-4-yl]benzenesulfonamide;
4-[2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide;
20 4-[2-benzyl-4-(3,4-difluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chlorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dichlorophenyl)oxazol-5-yl]benzenesulfonamide;
25 4-[2-benzyl-4-(4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethoxyphenyl)oxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3,4-dimethylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-chloro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
35 4-[2-benzyl-4-(4-chloro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-benzyl-4-(3-chloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
5 4-[2-benzyl-4-(3,5-dichloro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(3-fluoro-4-methylphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(4-fluoro-3-methylphenyl)oxazol-5-yl]benzenesulfonamide;
10 4-[2-benzyl-4-(3-fluoro-4-methoxyphenyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(2-thienyl)oxazol-5-yl]benzenesulfonamide;
15 4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(cyclohexyl)oxazol-5-yl]benzenesulfonamide;
4-[2-benzyl-4-(1-cyclohexenyl)oxazol-5-yl]benzenesulfonamide;
20 4-[2-(ethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(trifluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(difluoromethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
25 4-[2-(hydroxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(carboxy)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(methoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
30 4-[2-(ethoxycarbonyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(propyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(benzyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
35 4-[2-(phenoxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;

- 4-[2-((4-chlorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-((4-fluorophenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
5 4-[2-((4-carboxyphenoxy)methyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-phenethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(3-phenpropyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
10 4-[2-(carboxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(ethoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
15 4-[2-(methoxycarbonylmethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[2-(2-quinolyloxymethyl)-4-phenyloxazol-5-yl]benzenesulfonamide;
4-[5-(4-fluorophenyl)-2-methyl-oxazol-4-yl]benzenesulfonamide;
20 3-[5-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)oxazol-2-yl]propanoic acid;
methyl 3-[5-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)oxazol-2-yl]propanate;
25 4-[4-(4-fluorophenyl)-2-(2-phenylethyl)-oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-methyl-oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-phenyloxazol-5-yl]benzenesulfonamide;
30 4-[2-benzyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-(3-phenylpropyl)oxazol-5-yl]benzenesulfonamide;
35 4-[4-(4-fluorophenyl)-2-(n-propyl)oxazol-5-yl]benzenesulfonamide;

- 4-[2-(tert-butyl)-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
- 4-[4-(4-fluorophenyl)-2-(4-methoxyphenyl)methyloxazol-5-yl]benzenesulfonamide;
- 5 4-[4-(4-fluorophenyl)-2-(3-methoxyphenyl)methyloxazol-5-yl]benzenesulfonamide;
- 4-[2-diphenylmethyl-4-(4-fluorophenyl)oxazol-5-yl]benzenesulfonamide;
- 2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]acetic acid;
- 10 ethyl 2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]acetate;
- 3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanoic acid;
- 15 methyl 3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanate;
- 4-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]butanoic acid;
- methyl 4-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]butanate;
- 20 3-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]propanamide;
- ethyl 2-[4-(4-fluorophenyl)-5-[4-aminosulfonylphenyl]oxazol-2-yl]-2-benzyl-acetate;
- 25 4-[4-(4-fluorophenyl)-2-(cyclohexylethyl)oxazol-5-yl]benzenesulfonamide;
- 4-[4-(4-fluorophenyl)-2-(3-fluorophenoxymethyl)oxazol-5-yl]benzenesulfonamide;
- 4-[4-(4-fluorophenyl)-2-(3-chlorophenoxymethyl)oxazol-5-yl]benzenesulfonamide;
- 30 4-[4-(4-fluorophenyl)-2-(pyridyloxymethyl)oxazol-5-yl]benzenesulfonamide;
- 4-[4-(4-fluorophenyl)-2-phenoxymethyloxazol-5-yl]benzenesulfonamide;
- 35 4-[4-(4-fluorophenyl)-2-(2-hydroxyethyl)oxazol-5-yl]benzenesulfonamide;

- 4-[4-(4-fluorophenyl)-2-(hydroxymethyl)oxazol-5-yl]benzenesulfonamide;
4-[4-(cyclohexyl)-2-phenyloxazol-5-yl]benzenesulfonamide;
5 4-[4-(4-fluorophenyl)-2-benzyloxymethyloxazol-5-yl]benzenesulfonamide;
4-[4-(4-fluorophenyl)-2-cyclohexyloxazol-5-yl]benzenesulfonamide; and
4-[5-(4-fluorophenyl)-2-phenyloxazol-4-yl]benzenesulfonamide.
10

37. The method of Claim 25 for use in treatment of inflammation.

- 15 38. The method of Claim 25 for use in treatment of an inflammation-associated disorder.

39. The method of Claim 38 wherein the inflammation-associated disorder is arthritis.
20

41. The method of Claim 38 wherein the inflammation-associated disorder is pain.

42. The method of Claim 38 wherein the
25 inflammation-associated disorder is fever.

INTERNATIONAL SEARCH REPORT

Interns Application No
PCT/US 94/05395

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D263/32 A61K31/42 C07D413/12 C07D413/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 632 930 (DAVID J. CARINI ET AL) 30 December 1986 cited in the application see the whole document ---	1,13
A	US,A,3 901 908 (KONRAD FITZI ET AL) 26 August 1975 cited in the application see column 19, line 30 - column 19, line 35 ---	1
A	US,A,3 578 671 (KEVAN BROWN ET AL) 11 May 1971 cited in the application see the whole document ---	1,13-41
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 July 1994

Date of mailing of the international search report

04.08.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 94/05395

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF HETEROCYCLIC CHEMISTRY. vol. 22, no. 5 , September 1985 , PROVO US pages 1211 - 1214 RICHARD J. CREMLYN ET AL 'Some heterocyclic sulfonyl derivatives' cited in the application see the whole document ----	1-12
A	JOURNAL OF THE CHEMICAL SOCIETY 1963 , LETCHWORTH GB pages 1363 - 1370 T. VAN ES ET AL 'Substitution of 4,5-diphenyl-oxazoles and -imidazoles, and some related compounds' cited in the application see the whole document -----	1-12

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 25 - 41 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat

Application No

PCT/US 94/05395

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4632930	30-12-86	NONE	
US-A-3901908	26-08-75	NONE	
US-A-3578671	11-05-71	NONE	